

# UC Berkeley

## UC Berkeley Previously Published Works

### Title

Cryo-EM structure of SARS-CoV-2 ORF3a in lipid nanodiscs.

### Permalink

<https://escholarship.org/uc/item/01v7120w>

### Journal

Nature structural & molecular biology, 28(7)

### ISSN

1545-9993

### Authors

Kern, David M  
Sorum, Ben  
Mali, Sonali S  
[et al.](#)

### Publication Date

2021-07-01

### DOI

10.1038/s41594-021-00619-0

Peer reviewed



Published in final edited form as:

*Nat Struct Mol Biol.* 2021 July ; 28(7): 573–582. doi:10.1038/s41594-021-00619-0.

## Cryo-EM structure of SARS-CoV-2 ORF3a in lipid nanodiscs

David M. Kern<sup>1,2,3</sup>, Ben Sorum<sup>1,2,3,\*</sup>, Sonali S. Mali<sup>1,2,\*</sup>, Christopher M. Hoel<sup>1,2,3,\*</sup>, Savitha Sridharan<sup>1,2</sup>, Jonathan P. Remis<sup>3</sup>, Daniel B. Toso<sup>3</sup>, Abhay Kotecha<sup>4</sup>, Diana M. Bautista<sup>1,2,#</sup>, Stephen G. Brohawn<sup>1,2,3,#</sup>

<sup>1</sup>Department of Molecular & Cell Biology, University of California Berkeley, Berkeley, California 94720, USA

<sup>2</sup>Helen Wills Neuroscience Institute, University of California Berkeley, Berkeley, California 94720, USA

<sup>3</sup>California Institute for Quantitative Biology (QB3), University of California, Berkeley, CA 94720.

<sup>4</sup>Materials and Structural Analysis Division, Thermo Fisher Scientific, Eindhoven, The Netherlands

### Abstract

SARS-CoV-2 ORF3a is a putative viral ion channel implicated in autophagy inhibition, inflammasome activation, and apoptosis. 3a protein and anti-3a antibodies are found in infected patient tissues and plasma. 3a deletion in SARS-CoV-1 reduces viral titer and morbidity in mice, suggesting it could be an effective target for vaccines or therapeutics. Here, we present the first structures of SARS-CoV-2 3a by cryo-EM to 2.1 Å resolution. 3a adopts a novel fold with a polar cavity that opens to the cytosol and membrane through separate water- and lipid-filled openings. Hydrophilic grooves along outer helices could form ion conduction paths. Using electrophysiology and fluorescent ion imaging of 3a-reconstituted liposomes, we observe Ca<sup>2+</sup>-permeable, non-selective cation channel activity, identify mutations that alter ion permeability, and discover polycationic inhibitors of 3a activity. 3a-like proteins are found across coronavirus lineages that infect bats and humans, suggesting that 3a-targeted approaches could treat COVID-19 and other coronavirus diseases.

### Introduction

Coronavirus disease 2019 (COVID-19), caused by the SARS-CoV-2 virus, is an ongoing global pandemic. Vaccine and therapeutic development are predominantly focused on

#correspondence to dbautista@berkeley.edu or brohawn@berkeley.edu.

\*equal contributions

#### Author Contributions

BS, DMK, SSM, AK, DMB and SGB conceived of the project. DMK performed all molecular biology, biochemistry, preparation of proteoliposomes, and cryo-EM sample preparation. BS performed all electrophysiology. SSM designed and performed the YO-PRO-1, ruthenium red blocker, and Ca<sup>2+</sup> flux assays with help from DMB. CMH and DMK processed the cryo-EM data. SS performed light microscopy. JPR and DBT collected cryo-EM data at UC Berkeley and AK collected cryo-EM data at Thermo Fisher Scientific. SGB built and refined the atomic models. DMB and SGB secured funding and supervised research. DMK, BS, CMH, SSM, AK, DMB, and SGB wrote the manuscript with input from all authors.

#### Competing interests

Abhay Kotecha is an employee of Thermo Fisher Scientific. The other authors declare no competing interests.

the essential virus-encoded Spike, main protease, and RNA-dependent RNA polymerase proteins. High-resolution structures of these targets, some in complex with drug candidates or neutralizing antibodies, have yielded mechanistic insight into their function and have provided a platform for successful structure-guided vaccine and drug design<sup>1–6</sup>. Still, expanding our knowledge of SARS-CoV-2 target proteins remains important both for understanding SARS-CoV-2 virology and developing alternative treatments to mitigate against potential resistance that evolves, or new viruses that emerge, in the future<sup>7</sup>.

Virally encoded ORF3a (3a) has been considered a potential target for vaccines or therapeutics<sup>8,9</sup>. 3a is highly conserved within the *Betacoronavirus* subgenus *Sarbecovirus* which includes SARS-CoV-1 and other related bat coronaviruses (Supplemental Fig. 1)<sup>10</sup>. Biopsies from SARS-CoV-1 patients show 3a expression in infected tissue and SARS-CoV-1 and SARS-CoV-2 patient plasma contain anti-3a antibodies<sup>8,11–13</sup>. SARS-CoV-1 3a has been implicated in inflammasome activation<sup>14</sup> and both apoptotic<sup>15</sup> and necrotic cell death<sup>16</sup> while SARS-CoV-2 3a has been implicated in apoptosis and inhibition of autophagy *in vitro*<sup>17</sup>. In mouse models of both SARS-CoV-1 and 2 infection, genomic deletion of 3a reduces viral titer and morbidity<sup>18,19</sup>.

3a has been proposed to form an ion channel and is one of two putative viroporins encoded by the SARS-CoV-2 genome together with the envelope protein E (SARS-CoV-1 encodes an additional putative viroporin, ORF8a). SARS-CoV-1 3a has been reported to form an emodin- and Ba<sup>2+</sup>-sensitive cation channel<sup>20,21</sup>. Viroporins from other viruses have been shown to modify host membrane permeability to promote viral assembly and release<sup>22–24</sup>. However, the precise roles of 3a in disease pathogenesis are unknown, precluded in part by the lack of a mechanistic understanding of 3a. Here, we determine structures of SARS-CoV-2 3a by cryo-electron microscopy (cryo-EM) and assess putative ion channel activity *in vitro* using electrophysiology and fluorescent ion flux assays.

## Results

### Structure determination

We determined structures of dimeric and tetrameric SARS-CoV-2 3a in lipid nanodiscs. Full length SARS-CoV-2 3a was heterologously expressed in *Spodoptera frugiperda* (Sf9) cells with a cleavable C-terminal GFP tag. Purification of 3a in detergent resulted in two species separable by gel filtration (Extended Data Fig. 1). A majority of 3a runs at a position consistent with a 62 kDa dimer (Extended Data Fig. 1a,c,e) and ~10–30% runs as a 124 kDa tetramer (Extended Data Fig. 1). A similar degree of tetramer formation was observed at low concentrations of 3a by fluorescence size-exclusion chromatography, indicative of a biochemically stable species rather than concentration-dependent nonspecific aggregation (Extended Data Fig. 1e). These data are consistent with previous reports of dimeric and tetrameric SARS-CoV-1 3a observed by western blot<sup>16,20</sup>.

We separately reconstituted dimeric and tetrameric SARS-CoV-2 3a into nanodiscs made from the scaffold protein MSP1E3D1 and a mixture of DOPE, POPC, and POPS lipids and determined their structures by cryo-EM to 2.9 Å and 6.5 Å resolution (Extended Data Figs. 2–4, Supplemental Data Fig. 2, Table 1). Based on a report of improved resolution

of apoferritin and GABA<sub>A</sub> structures using new cryo-EM instrumentation (including the electron source, energy filter, and camera; see Methods for details)<sup>25</sup>, we asked whether similar improvements would be possible for the sub-100 kDa 3a. Indeed, a reconstruction generated from data collected on this instrumentation, using the same batch of grids, was significantly improved to 2.1 Å (Fig. 1, Extended Data Fig. 2 and 5, Supplemental Data Fig. 4, Table 1). We note we cannot exclude other differences including in accelerating voltage, pixel size, or defocus range from potentially contributing to the improvement in resolution.

### 3a dimer structure

The 2.9 Å dimeric reconstruction (with C2 symmetry applied, PDB 6XDC) permitted de novo modeling of 195 of the 275 amino acids per protomer chain. The N-terminus (amino acids 1–39), C-terminus (amino acids 239–275), and a short cytoplasmic loop (amino acids 175–180) are weakly resolved in the density map due to conformational differences between particles or because they are disordered (Supplemental Fig. 2 and Extended Data Fig. 3). The 2.1 Å dimeric reconstruction (with C2 symmetry applied, PDB 7KJR) allowed for improved rotamer assignments due to better defined side chain density throughout the protein, including visible holes in many aromatic residues (Fig. 1a–f). We additionally modelled a portion of each MSP1E3D1 scaffold protein (amino acids 25–55, Fig. 1g,h), two DOPE lipids, and 122 water molecules. We refer to the higher resolution structure in the remainder of the manuscript unless otherwise indicated. The scaffold protein is partially well-resolved largely due to a specific interaction visible on each side of the 3a dimer (even in C1 reconstructions) between MSP1E3D1 W40 and the transmembrane region of 3a (Fig. 1g,h). The symmetric nature of this interaction means that the two MSPE3D1 protomers must twist around the lipid bilayer rather than adopting the canonical arrangement of two parallel stacked rings.

3a adopts a novel fold that, to our knowledge, has not been observed in available protein structures. Querying the protein structure database for homologs with Dali returned only weak hits for fragments of 3a domains<sup>26</sup>. Viewed from the membrane plane, 3a is approximately 70 Å tall with a 40 Å high transmembrane region and a cytosolic domain (CD) extending 30 Å out of the membrane (Fig. 1a,b). The transmembrane region is composed of three helices per protomer with N-termini oriented on the extracellular or luminal side and C-termini on the cytosolic side of the membrane. Viewed from the extracellular side, the transmembrane helices (TMs) trace the circumference of an ellipse with TM1-3 from one protomer followed by TM1-3 of the second protomer in a clockwise order (Fig. 1c). TM1s and TM2s pack against each other across the elliptical minor axis with TM3s positioned at the major axis vertices. TM1-TM2 and TM2-TM3 are joined by short intracellular and extracellular linkers, respectively.

The transmembrane region connects to the CD through a turn-helix-turn motif following TM3. Each protomer chain forms a pair of opposing β-sheets packed against one another in an eight stranded β-sandwich (Fig. 1b,d). The outer sheet is formed by strands β1, β2, β6 and the N-terminal half of β7. The inner sheet is formed by strands β3, β4, β5, β8, and C-terminal half of β7. The inner sheets from each protomer interact through a large (~940 Å<sup>2</sup> buried surface area per chain) and highly complementary interface with residues V168,

V225, F230, and I232 forming a continuous hydrophobic core (Fig. 1d). The interaction between  $\beta$ -sandwiches from each protomer thus forms a strong and stable link between monomers in the dimer.

### Structural features of 3a tetramers

We next examined the structure of 3a tetramers. Two-dimensional class averages of tetrameric 3a show a side-by-side arrangement of two dimers with separated TMs and close juxtaposition of CDs (Fig. 2a). Tetrameric 3a reconstructions had lower final resolutions ( $\sim 6.5$  Å) than dimeric 3a (Fig. 2a, Extended Data Fig. 2), which precluded detailed model building, but were sufficiently featured in the CDs for rigid-body docking of two copies of the 3a dimer to determine their approximate relative orientation (Fig. 2b, Extended Data Fig. 6a). The best fit model shows a continuous interface ( $\sim 300$  Å<sup>2</sup> buried surface area per dimer) formed between TM3-CTD linkers and  $\beta 1$ - $\beta 2$  linkers from neighboring dimers. While the exact positions of side chains cannot be determined at this resolution, residues W131, R134, K136, H150, T151, N152, C153, and D155 are poised to mediate tetramerization through a network of hydrophobic, polar, and electrostatic interactions (Fig. 2c). In SARS-CoV-1 3a, reducing agents and a C133A mutation resulted in loss of oligomerization, membrane localization, and ion channel activity<sup>20</sup>. However, expression of the C133A mutant was dramatically reduced, suggesting these results might be a consequence of protein destabilization<sup>20</sup>. In SARS-CoV-2 3a, C133 is located in a notable cysteine-rich pocket adjacent to the tetramerization interface (Extended Data Fig. 6b). At the base of TM3, C133 projects back towards the top faces of  $\beta 1$  and  $\beta 2$  in close proximity to solvent exposed C148 and buried C157. All three cysteines are reduced in the structure, though they are within potential disulfide-bonding distance (Ca distance 4.4–6.5 Å) (Extended Data Fig. 6b). While it is unlikely a disulfide involving C133 mediates tetramerization of 3a without significant rearrangement of this region, it could be that disruption of this cysteine-rich pocket with cysteine modifying agents or mutations disfavors 3a oligomerization allosterically.

### Potential ion permeation paths through 3a

Ion conduction pathways are required for ion channel function, so we analyzed the 3a structures to identify potential permeation routes. 3a forms a large polar cavity within the inner half of the TM region. The cavity is continuous with the cytosol and surrounding bilayer through three pairs of openings: the upper, lower, and intersubunit tunnels (Fig. 3a–f). The upper tunnels are formed between TM2 and TM3 within each protomer, narrow to  $\sim 2.2$  Å in radius, and likely open to the membrane (Fig. 3a–c). The lower tunnels run underneath the TM1-TM2 linker and above the CD, narrow to  $\sim 2$  Å in radius, and open to the cytosol (Fig. 3a,d,e). The lower tunnels are open paths for ion and water movement between the cell interior and channel cavity. Consistently, a network of ordered water molecules extends through these openings, the cavity, and the CD (Fig. 3b,d). The intersubunit tunnels run between TM1 and TM3 from opposing protomers, just above the CD, and open to the membrane-cytosol interface (Fig. 3a,f). Strong lipid-shaped density present within each intersubunit tunnel is modeled as DOPE (the most abundant lipid in these nanodiscs) with the ethanolamine head group pointed into the cavity. Lipid binding is stabilized by electrostatic interactions: the positively charged ethanolamine interacts with

negatively charged D142 and the backbone carbonyls of I63 and D142 while the lipid phosphate interacts with R126, R122, Y206, N144, and the backbone amide of L65.

While the polar cavity reduces the energetic barrier to ion movement across the inner half of the low dielectric membrane, the current structures lack a central pore connecting the cavity to the luminal or extracellular side. Instead, a hydrophobic seal is formed between transmembrane helices in the extracellular half of the membrane above the polar cavity (Fig. 3). The top of the cavity is formed by polar interactions between Q57, S58, N82, and Q116 side chains (Fig. 3a,g). Just extracellular to these interactions, the hydrophobic seal is formed by interactions between residues F43, L46, I47, V50, L95, and L96 (Fig. 3a,h,i). Opening a central pore would require substantial conformational rearrangement to break these hydrophobic interactions.

Most ion channels have central pores for conduction, but some, including those of the TMEM16 and OSCA families, have evolved ion pathways through external grooves or tunnels near membrane facing surfaces<sup>27–30</sup>. 3a exhibits a distinctive membrane-facing, partially hydrophilic groove is observed between TM2 and TM3 (Fig. 3j). It is bounded by the upper tunnel and TM2-TM3 linker at the cytoplasmic and extracellular sides, respectively, and is lined by conserved polar residues N119, N82, S117, Q116, S58, T89, Y113, S92, Y109, and H93 (Fig. 3k). The hydrophilic character of this region would be expected to lower the energetic barrier for movement of ions across the outer half of the membrane and more subtle conformational changes would be required to permit permeation along this route relative to a central pore. 3a oligomerization could also be important for building a conduction path either through conformational changes or pore assembly, as was proposed for SARS-CoV-1 3a<sup>20</sup>. While a pore is not formed in the context of the SARS-CoV-2 tetramer, we observe that one of the partially hydrophilic TM2-TM3 grooves from each dimeric unit face one another across a narrow membrane (Extended Data Fig. 6c).

### Assessment of channel activity in 3a-reconstituted proteoliposomes

We next utilized electrophysiology and calcium imaging to assess whether SARS-Cov-2 3a is capable of permeating ions. We did not observe consistent currents in recordings from transfected cells and reasoned this could be due to the majority of 3a being localized to internal membranes (Extended Data Fig. 7), inactivation at the plasma membrane, and/or 3a toxicity. We therefore purified 3a in detergent, reconstituted it into phosphatidylcholine-containing proteoliposomes, and recorded currents across excised patches pulled from proteoliposome blisters. Excised patches from 3a-containing liposomes exhibited currents that reversed at 0 mV and displayed modest outward rectification in symmetric [K<sup>+</sup>] (Fig. 4a, Extended Data Fig. 8). In contrast, channel-like activity was not observed in recordings from mock-reconstituted (empty) proteoliposomes (Extended Data Fig. 8g). We evaluated ion selectivity of 3a by replacing the K<sup>+</sup>-containing bath solution with solutions containing Na<sup>+</sup>, NMDG<sup>+</sup>, or Ca<sup>2+</sup>. Solution exchange resulted in reversal potential shifts from 0.3 ± 0.3 mV in K<sup>+</sup> to -8.2 ± 0.8 mV in Ca<sup>2+</sup>, -13.5 ± 1.8 mV in Na<sup>+</sup>, and -31.0 ± 1.1 mV in NMDG<sup>+</sup> (Fig. 4B,D). These shifts correspond to the following permeability ratios (P<sub>X</sub>/P<sub>K<sup>+</sup></sub>): Ca<sup>2+</sup> (1.88±0.08) > K<sup>+</sup> (1.0±0.01) > Na<sup>+</sup> (0.59±0.04) > NMDG<sup>+</sup> (0.29±0.01) (Fig. 4C). Alkaline or acidic pH had little effect on channel activity (Extended Data Fig.

8f). Consistent with the electrophysiological measurements, we also observed significant calcium influx in 3a-proteoliposomes using Fluo-5N calcium imaging following the addition of 8mM  $[Ca^{2+}]_{ext}$  compared to empty liposomes (Fig. 4e).

We performed mass spectrometry of 3a samples to assess whether channel activity observed in vitro could be due to channel contaminants in purified 3a or lipids used for reconstitution. We analyzed samples of 3a in detergent prior to liposome incorporation, 3a reconstituted-proteoliposomes, and mock-reconstituted liposomes and searched a database consisting of the 3a construct, the *S. frugiperda* (expression system) proteome, the *G. max* (lipid source) proteome, and common contaminants (Extended Data Fig. 9). We detected significant 3a peptides in both 3a-containing samples, with the detergent sample giving better sequence coverage and more matched peptides. The only other proteins identified were at low levels and from common contaminants; no peptides from known channels or transmembrane proteins other than 3a were observed in any sample. While we cannot definitively rule out the presence of an unannotated contaminant or one below the detection threshold for mass spectrometry, these results suggest SARS-CoV-2 3a is responsible for the  $Ca^{2+}$ -permeable nonselective channel activity observed in vitro.

### Polycations block 3a channel activity in vitro

We next asked whether blockers of non-selective cation channels inhibit 3a ion conduction in liposomes. We found that Ruthenium Red (RuR), a 786 Da polycationic dye, blocks 3a activity in current recordings (Fig. 4g–h) and  $Ca^{2+}$  influx measurements (Fig. 4e). RuR displays dose-dependent inhibition of 3a activity in proteoliposome recordings ( $IC_{50}=90 \pm 10 \mu M$ ) with flickery block at negative potentials, similar to that observed with other large pore channels (Fig. 4g). In addition, we identified the polyamine spermidine, which showed near complete block at 10 mM, and the trivalent ions  $Gd^{3+}$ ,  $Fe^{3+}$ , and  $Tb^{3+}$ , which showed partial block at 1–10 mM, as 3a inhibitors in proteoliposome recordings (Fig. 4g). RuR, spermidine,  $Gd^{3+}$ , and other trivalents are relatively nonselective inhibitors of cation channels including TRPs, RyRs, CALHMs, K2Ps, and  $K_{IRs}^{31-37}$ , but the spectrum of 3a blockers and affinities observed here is, to our knowledge, distinct from those of other known channels. We further tested reported low-affinity blockers of SARS-CoV-1 3a channel activity<sup>20,21</sup>, but found that neither  $Ba^{2+}$  or the small molecule emodin inhibited SARS-CoV-2 3a activity (Extended Data Fig. 8d,e). Consistently, in a cryo-EM structure of dimeric 3a determined in the presence of 100  $\mu M$  emodin to 3.7 Å resolution (Extended Data Fig. 2 and 4, Supplemental Data Fig. 3, Table 1), we observed no evidence of emodin binding or significant structural changes compared to apo-3a.

### 3a permeates the large divalent ion YO-PRO-1

Given the ability of 3a channels to weakly conduct  $NMDG^+$  (Fig. 4a–d), we next used a YO-PRO-1 fluorescence-based flux assay to assess the ability of 3a channels to conduct other large cations. YO-PRO-1, a 629 Da divalent cation, does not readily cross lipid bilayers and has been used to study the activity of other non-selective cation channels, including P2X7 and TRP channels, that can conduct large organic cations<sup>31,32,38,39</sup>. Robust YO-PRO-1 uptake was observed in a subset of 3a liposomes that was significantly higher than background fluorescence observed in empty liposomes (Fig. 5a–d). To compare YO-PRO-1

uptake across multiple experiments, we quantified a single value (area under the curve) to represent both the number of YO-PRO-1+ liposomes and the amount of YO-PRO-1 uptake (Fig. 5e). Using this analysis, we found 3a-liposomes display significantly greater YO-PRO-1 uptake and accumulation as compared to empty liposomes (Fig. 5e). Uptake was dependent on 3a protein because liposomes containing the human K2P channel TRAAK displayed little uptake and accumulation of YO-PRO-1, similar to empty liposomes, as expected for a highly selective K<sup>+</sup> channel (Fig. 5A, C–E). Similar to current recordings (Fig. 4e–f), we observed a dose-dependent RuR block of 3a activity in the YO-PRO-1 flux assay ( $IC_{50}=175 \pm 98 \mu\text{M}$ ). These data suggest 3a can form an ion channel that is capable of passing large cations. RuR (786 Da) block and YO-PRO-1 (629 Da) and NMDG<sup>+</sup> (406 Da) permeation sets limits on 3a pore size that are similar those observed for TRP and P2X channels.

### 3a mutants alter ion conduction

We speculate that, relative to the structures presented here, an open conformation of 3a involves substantial rearrangement of the hydrophobic seal to create a central pore or more subtle rearrangement of the partially hydrophilic membrane facing grooves between TM2 and TM3 to create lateral conduction pathways. To probe the structural determinants for 3a ion conduction, we set out to identify 3a mutations that alter channel activity. To this end, we purified nine mutated or truncated 3a constructs, reconstituted each into proteoliposomes, and compared them to wild-type 3a in electrophysiological recordings (Fig. 6a, Extended Data Fig. 10). We find that two separate mutants alter channel activity, one at the top of the cavity (Q57E) and another at the base of the TM2-TM3 grooves (S58L,Q116L). Both Q57E and S58L,Q116L mutants reduce Ca<sup>2+</sup> and NMDG<sup>+</sup> permeability without altering Na<sup>+</sup> or K<sup>+</sup> permeability. These effects were specific to these mutations as seven additional mutations, including a common circulating variant Q57H<sup>40</sup>, had no effect on relative ion permeability. These results are consistent with the hypothesis that 3a channel opening involves conformational changes of residues that form constrictions above the polar cavity or along the hydrophilic membrane-facing TM2-TM3 grooves.

Our structural analysis revealed an unassigned region of density in the cryo-EM maps stretching between subunits just above the extracellular side of the transmembrane region and near the top of the TM2-TM3 grooves that likely corresponds to a portion of the unmodeled N-terminus (Extended Data Fig. 7). To investigate the potential role of the N-terminus in channel function, we generated an N-terminal deletion construct lacking the first 41 amino acids (3a<sup>N</sup>). This mutant displayed reduced Ca<sup>2+</sup> and NMDG<sup>+</sup> relative permeability in proteoliposome recordings, albeit to a lesser extent than Q57E and S58L,Q116L (Figure 6b). The relative permeability changes observed in liposomes suggest that residues in the N-terminus, like those at the top of the polar cavity, mediate the ability of 3a to permeate large cations. In addition, the N-terminus may be involved in 3a subcellular localization as 3a<sup>N</sup> channels displayed increased localization to the plasma membrane (Extended Data Fig. 7).



### 3a-like proteins in *Alpha-* and *Beta-coronavirus*

While 3a is well conserved in the *Betacoronavirus* subgenus (Supplemental Fig. 1), related proteins have not yet been identified in other coronaviruses, including the other five species known to infect humans: MERS-CoV, HCoV-NL63, HCoV-229E, HCoV-HKU1, and HCoV-OC43. Thus, we asked whether we could identify more distant homologs using the 3a structure and structure prediction algorithms. 3a homologs were not detected in *Gammacoronavirus*, *Deltacoronavirus*, or in the *Betacoronavirus* subgenus *Embecovirus* (which includes HCoV-HKU1 and HCoV-OC43). Distant homology to the CD was identified in the membrane protein ORF5 found in *Betacoronavirus* subgenus *Merbecovirus* species including MERS-CoV. We identified high confidence structural homologs in all remaining *Betacoronavirus* and *Alphacoronavirus* subgenera (including in HCoV-229E and HCoV-NL63 (Supplemental Fig. 5), several of which have also been reported to have ion channel activity<sup>41–43</sup>. Notably, coronaviruses with 3a homologs have been proposed to derive from viruses that circulate primarily in bats, while coronaviruses without 3a structural homologs have been proposed to derive from viruses that circulate primarily in rodents, birds, or pigs (Table 2). It may be that the presence of 3a in coronaviruses with bats as their principal reservoir reflects a unique aspect of bat coronavirus biology.

## Discussion

Together, our data demonstrate that SARS-CoV-2 3a adopts a novel dimeric fold widely conserved across Coronaviridae and can form a non-selective Ca<sup>2+</sup> permeable cation channel. These results provide a basis for further studies to determine the basis for 3a channel gating and conduction. A polar cytoplasmic cavity creates a low energy path for ions to traverse between the cytoplasm and halfway across the membrane. However, 3a lacks a central pore across the outer half of the membrane and conformational changes to open a central pore would require breaking interactions that form a hydrophobic seal between transmembrane helices in the current structure. Alternatively, lateral conduction pathways could be formed along conserved hydrophilic membrane-facing grooves between TM2 and TM3. Similar lateral conduction paths have precedence among other channels including members of the TMEM16 and OSCA families<sup>27–30</sup>.

Oligomeric 3a assemblies could also mediate 3a activation. 3a dimers associate into tetramers and assembly could feasibly be propagated further into higher order oligomers. Consistently, we observe increased oligomeric 3a bands in SDS-PAGE gels after liposome incorporation (Extended Data Fig. 1 and 10). This observation, together with the lipid binding pocket within 3a and its localization to organellar membranes, suggests the membrane environment may be important for 3a structure and function.

In liposomes, SARS-CoV-2 3a exhibits permeability to large cations including NMDG<sup>+</sup> and YO-PRO-1 and sensitivity to RuR and Gd<sup>3+</sup>, broadly reminiscent of other Ca<sup>2+</sup>-permeable channels including TRPV1, TRPA1, and P2X7<sup>31,32</sup> while displaying, to our knowledge, a unique functional fingerprint. We note that our data are only partially consistent with previously reported properties of SARS-CoV-1 3a. For example, we do not observe block by Ba<sup>2+</sup> or emodin and while both proteins apparently form non-selective cation channels, their relative permeability for cations differs. This could be explained by sequence and functional

divergence: 3a in the two viruses shares just 73% sequence identity. Alternatively, different recording and lipid environments might alter channel properties. SARS-CoV-1 3a activity was recorded in *Xenopus* oocytes or cultured cells, while SARS-CoV-2 3a activity was recorded in reconstituted membranes. Whether SARS-CoV-2 3a channel activity is observed in cells, perhaps in intracellular membranes where the majority of heterologously expressed protein is localized, remains to be determined.

If 3a has channel activity in cells, it could be important for promoting viral maturation in cells through inhibition of autophagy and disruption of lysosomes<sup>44,45</sup>. The unresolved N- and C- termini may also play important roles in determining 3a's localization and binding partners. The calcium permeability of 3a is of particular interest in the context of infection. SARS-CoV-2 3a has been recently shown to trigger programmed cell death in cultured cells<sup>17</sup> and calcium influx through 3a could serve as a switch that activates calcium-dependent caspases and apoptosis. Previous studies showed SARS-CoV-1 3a expression in infected lung pneumocytes, a key cell type also infected by SARS-CoV-2, and calcium signaling in type II pneumocytes plays an important role in maintaining airway homeostasis<sup>46,47</sup>. Thus, the expression of a calcium permeable channel, like SARS-CoV-2 3a, could impact lung homeostasis and COVID-19 pathogenesis. Our data suggest that 3a could represent a new target for treating COVID-19 and other coronavirus diseases and points the way to future experiments to elucidate the role of 3a in the viral life cycle and disease pathology.

## Methods

### Cloning and protein expression

The coding sequence for the 3a protein from SARS-Cov-2 was codon optimized for *Spodoptera frugiperda* (Sf9 cells) and synthesized (IDT, Newark, NJ). The sequence was then cloned into a custom vector based on the pACEBAC1 backbone (MultiBac; Geneva Biotech, Geneva, Switzerland) with an added C-terminal PreScission protease (PPX) cleavage site, linker sequence, superfolder GFP (sfGFP) and 7xHis tag, generating a construct for expression of 3a-SNS-LEVLFGQP-SRGGSGAAAGSGSGS-sfGFP-GSS-7xHis. Mutants and truncation were also introduced into this construct using PCR. MultiBac cells were used to generate a Bacmid according to manufacturer's instructions. Sf9 cells were cultured in ESF 921 medium (Expression Systems, Davis, CA) and P1 virus was generated from cells transfected with Escort IV reagent (MilliporeSigma, Burlington, MA) according to manufacturer's instructions. P2 virus was then generated by infecting cells at 2 million cells/mL with P1 virus at a MOI ~0.1, with infection monitored by fluorescence and harvested at 72 hours. P3 virus was generated in a similar manner to expand the viral stock. The P2 or P3 viral stock was then used to infect Sf9 cells at 4 million cells/mL at a MOI ~2–5. At 72 hours, infected cells containing expressed 3a-sfGFP protein were harvested by centrifugation at  $2500 \times g$  for 10 minutes and frozen at  $-80^{\circ}\text{C}$ .

### Protein purification

For preparation of the 3a dimer and mutant constructs, infected Sf9 cells from 1 L of culture (~15–20 mL of cell pellet) were thawed in 100 mL of Lysis Buffer containing

50 mM Tris, 150 mM KCl, 1mM EDTA pH 8. Protease inhibitors (Final Concentrations: E64 (1  $\mu$ M), Pepstatin A (1  $\mu$ g/mL), Soy Trypsin Inhibitor (10  $\mu$ g/mL), Benzamidine (1 mM), Aprotinin (1  $\mu$ g/mL), Leupeptin (1 $\mu$ g/mL), AEBSF (1mM), and PMSF (1mM)) were added to the lysis buffer immediately before use. Benzonase (4  $\mu$ l) was added after the cell pellet thawed. Cells were then lysed by sonication and centrifuged at 150,000  $\times$  g for 45 minutes. The supernatant was discarded and residual nucleic acid was removed from the top of the membrane pellet using DPBS. Membrane pellets were scooped into a dounce homogenizer containing Extraction Buffer (50 mM Tris, 150 mM KCl, 1 mM EDTA, 1% n-Dodecyl- $\beta$ -D-Maltopyranoside (DDM, Anatrace, Maumee, OH), pH 8). A 10% stock solution of DDM was dissolved and clarified by bath sonication in 200 mM Tris pH 8 prior to addition to buffer to the indicated final concentration. Membrane pellets were then homogenized in Extraction Buffer and this mixture (150 mL final volume) was gently stirred at 4°C for 1 hour. The extraction mixture was centrifuged at 33,000  $\times$  g for 45 minutes and the supernatant, containing solubilized membrane protein, was bound to 4 mL of Sepharose resin coupled to anti-GFP nanobody for 1 hour at 4°C. The resin was then collected in a column and washed with 10 mL of Buffer 1 (20 mM HEPES, 150 mM KCl, 1 mM EDTA, 0.025% DDM, pH 7.4), 40 mL of Buffer 2 (20 mM HEPES, 500 mM KCl, 1 mM EDTA, 0.025% DDM, pH 7.4), and 10 mL of Buffer 1. The resin was then resuspended in 6 mL of Buffer 1 with 0.5 mg of PPX protease and rocked gently in the capped column for 2 hours. Cleaved 3a protein was then eluted with an additional 8 mL of Wash Buffer, spin concentrated to ~500  $\mu$ l with Amicon Ultra spin concentrator 10 kDa cutoff (Millipore), and then loaded onto a Superdex 200 increase column (GE Healthcare, Chicago, IL) on an NGC system (Bio-Rad, Hercules, CA) equilibrated in Buffer 1. Peak fractions containing 3a channel were then collected and spin concentrated prior to incorporation into proteoliposomes or nanodiscs. For the tetramer, the preparation was carried out in a similar manner, except with overnight protease cleavage and collection of a peak of larger hydrodynamic radius (see Extended Data Fig. 1). Traces for gel filtration were prepared using Chromlab 6.0 (Bio-Rad), Prism 8, and Adobe Illustrator.

### Proteoliposome formation

For proteoliposome patching experiments, we incorporated protein into lipid and generated proteoliposome blisters for patch recordings using dehydration and rehydration as described previously with the following modifications<sup>48</sup>. 3a dimer was first purified into Buffer 1. Protein was then exchanged into lipid with the addition of Biobeads SM2 (Bio-Rad, Hercules, CA) and an overnight incubation at a protein:lipid ratio of 1:10 (corresponding to 0.5 mg purified 3a dimer and 5 mg of cleared Soybean L- $\alpha$ -phosphatidylcholine (Soy PC, MillaporeSigma, Burlington, MA) in DR Buffer (5 mM HEPES, 200 mM KCl, pH7.2). For the YO-PRO-1 assay, 3a was incorporated at a ratio of 1:50. TRAAK control proteoliposomes were prepared at 1:50 as described previously<sup>48</sup>. Control liposomes were prepared from the same lipid mix and protocol with protein replaced with Buffer 1.

### Electrophysiology

All electrophysiology recordings were made from 3a-reconstituted Soy PC proteoliposomes. Patches formed in an inside-out configuration and were quickly (within 5–10 seconds) transferred to a solution exchange chamber. Recordings were made at room temperature

using Clampex 10.7 data acquisition software (as part of pClamp 10.7 suite) with an Axopatch 200B Patch Clamp amplifier and Digidata 1550B digitizer (Molecular Devices) at a bandwidth of 1 kHz and digitized at 500 kHz. A pressure clamp (ALA Scientific) was used to form seals. Potassium pipette and bath solution was 5 mM HEPES pH 7.2, 150 mM KCl. Sodium bath solution was 5 mM HEPES pH 7.2, 150 mM NaCl. NaCl in the bath solution was substituted for 150 mM NMDG-Cl or 75 mM CaCl<sub>2</sub> for permeability experiments. Borosilicate glass pipettes were pulled and polished to a resistance of 2–5 MΩ when filled with pipette solution. For cation permeability experiments, liquid junction potentials were calculated and data were corrected offline. For current-voltage plots, the following voltage protocol was applied:  $V_{\text{hold}} = 0$  mV;  $V_{\text{test}} = -100$  to  $+100$  mV,  $20$  mV,  $t_{\text{test}} = 1$  second. Currents from each patch correspond to mean values during the step to the indicated voltage.

Permeability ratios were calculated according to Goldman-Hodgkin-Katz relationship. For monovalent cations, permeability ratios were calculated as  $P_{X^+}/P_{K^+} = \exp(-V_{\text{rev}}F/RT)$ . For divalent cations, permeability ratios were calculated as:  $P_{X^{2+}}/P_{K^+} = \alpha_{K^+} [K^+] \exp(-V_{\text{rev}}F/RT) (1 + \exp(-V_{\text{rev}}F/RT)) / 4\alpha_{X^{2+}} [X^{2+}]$  where  $V_{\text{rev}}$  is the reversal potential,  $F$  is Faraday's constant,  $R$  is the universal gas constant, and  $T$  is absolute temperature (where  $RT/F = 25.2$  mV at room temperature), and  $\alpha$  is the ion activity coefficient (assumed to be 0.75 for K<sup>+</sup> and 0.25 for Ca<sup>2+</sup>).

## Mass Spectrometry

Samples from 3a in DDM (prior to liposome incorporation), 3a in soy PC (1:50 ratio, and tested for activity in both electrophysiological and fluorescence-based assays) or control liposomes were run on SDS-PAGE gels and stained (See Extended Data Fig. 9). For the DDM sample, the entire gel lane above the dye front was excised, including the stacking gel. For samples with lipid, to minimize lipid interference in sample digestion, the gel lane above the stained lipid was then excised (which includes the region ~15kDa and larger).

Mass spectrometry was performed by the Vincent J. Coates Proteomics/Mass Spectrometry Laboratory at UC Berkeley. The excised gel lanes were digested with trypsin in situ, and the resulting peptides extracted and concentrated. A nano LC column was packed in a 100 μm inner diameter glass capillary with an emitter tip. The column consisted of 10 cm of Polaris c18 5 μm packing material (Varian). The column was loaded by use of a pressure bomb and washed extensively with buffer A (5% acetonitrile/0.02% heptafluorobutyric acid (HBFA)). The column was then directly coupled to an electrospray ionization source mounted on a Thermo-Fisher LTQ XL linear ion trap mass spectrometer. An Agilent 1200 HPLC equipped with a split line so as to deliver a flow rate of 300 nl/min was used for chromatography. Peptides were separated with a reverse phase elution using a gradient of 5% to 60% acetonitrile generated by a transition from buffer A to buffer B (60% acetonitrile/0.02% HBFA) over 90 minutes.

Protein identification was done with Integrated Proteomics Pipeline (IP2, Integrated Proteomics Applications, Inc San Diego, CA) using ProLuCID/Sequest, DTASelect2 and Census<sup>49,50,51</sup>. Tandem mass spectra were extracted into ms1 and ms2 files from raw files using RawExtractor<sup>52</sup>. Data was searched against a *Spodoptera frugiperda* protein database from Uniprot with the added amino acid sequence of purified 3a (including the cleavage

site scar), supplemented with sequences of common contaminants, and concatenated to form a decoy database<sup>53</sup>. Searches against soy (*Glycine max*) returned no significant hits for any sample. LTQ data was searched with 3000.0 milli-amu precursor tolerance and the fragment ions were restricted to a 600.0 ppm tolerance. All searches were parallelized and searched on the VJC proteomics cluster. Search space included all half tryptic peptide candidates with no missed cleavage restrictions. Carbamidomethylation (+57.02146) of cysteine was considered a static modification. In order to identify authentic termini, we required one tryptic terminus for each peptide identification. The ProLuCID search results were assembled and filtered using the DTASelect program with a peptide false discovery rate (FDR) of 0.001 for single peptides and a peptide FDR of 0.005 for additional peptides for the same protein. Under such filtering conditions, the estimated false discovery rate was less than 1%.

### Ca<sup>2+</sup> uptake assay in proteoliposomes

Fluo-5N was incorporated into 3a-reconstituted proteoliposomes and control liposomes by first thawing frozen liposomes at a ratio of ~1:20 (v:v) into modified sucrose formation buffer<sup>54</sup> 25 mM HEPES pH 7.4, 150 mM KCl, and 262 mM Sucrose with a final concentration of 25  $\mu$ M Fluo-5N (Stock concentration 5 mM in DMSO, AAT Bioquest). Next, the liposome mixtures in Eppendorf tubes were placed in a foam flotation in an ice bath and sonicated with a Branson Digital Sonifier 450 for 30 seconds total (10% Amplitude, 10 second pulse with 59 second wait time). Excess (unincorporated) Fluo-5N was then removed using microspin G-50 columns (Cytiva). The sample was then diluted into solution containing 50mM HEPES, 300mM KCl, and 2mM EGTA, pH=7.4 and plated onto poly-D-lysine (Sigma-Aldrich, 1mg/ml) coated 96-well plates, and centrifuged ( $440 \times g$  for 5 min) at room temperature. Ca<sup>2+</sup> influx was measured upon addition of a 50 mM HEPES, 285 mM KCl, 10 mM CaCl<sub>2</sub>, pH=7.4 solution. Images were acquired every 3 seconds for a total of 150 seconds. Fluorescence intensity of each liposome was normalized to its average fluorescence prior to Ca<sup>2+</sup> addition.

### YO-PRO-1 flux assay

Liposomes were diluted in saline solution containing 300mM KCl, 50mM HEPES, pH=7.4 and plated onto poly-D-lysine (Sigma-Aldrich, 1mg/ml) coated 96-well plates, centrifuged ( $5,000 \times g$  for 5 min) and incubated in 10 $\mu$ M YO-PRO-1 iodide (Invitrogen) for 10 min at room temperature. Liposomes were rinsed with saline solution to remove free YO-PRO-1. Images were acquired using an ImageXpress Micro XLS microscope with a solid-state light source and 20X air objective. Images were analyzed using MetaXpress 6 software (Molecular Devices). Empty liposomes displayed low-level fluorescence in the 488/540nm range. Thus, liposomes were defined as YO-PRO-1+ if their fluorescence intensity was above the average intensity of unlabeled, empty liposomes. To calculate the total number of liposomes, we quantified the total number of liposomes using auto segmentation on MetaXpress 6 from brightfield images. Stock solutions of Ruthenium red (Tocris) were prepared in water, diluted in bath solution and applied to liposomes or cells 10min before the start of the experiment. All statistical tests were performed using Prism (GraphPad). Values are reported as the mean  $\pm$  SD or mean  $\pm$  SEM as indicated. Mann Whitney or a one-way

or Welch's ANOVA followed by the Dunnett's, Sidak's, or Tukey's post hoc tests (where appropriate) were used for statistical comparisons.

### Nanodisc Formation

Freshly purified 3a dimer in Buffer 1 was reconstituted into MSP1E3D1 nanodiscs with a mixture of lipids (DOPE:POPS:POPC at a 2:1:1 mass ratio, Avanti, Alabaster, Alabama) at a final molar ratio of 1:4:400 (Monomer Ratio: 3a, MSP1E3D1, lipid mixture). First, 20 mM solubilized lipid in Nanodisc Formation Buffer (20 mM HEPES, 150 mM KCl, 1 mM EDTA pH 7.4) was mixed with additional DDM detergent and 3a protein. This solution was mixed at 4°C for 30 minutes before addition of purified MSP1E3D1. This addition brought the final concentrations to approximately 15  $\mu$ M 3a, 60  $\mu$ M MSP1E3D1, 6 mM lipid mix, and 10 mM DDM in Nanodisc Formation Buffer. The solution with MSP1E3D1 was mixed at 4°C for 10 minutes before addition of 200 mg of Biobeads SM2. Biobeads (washed into methanol, water, and then Nanodisc Formation Buffer) were weighed after liquid was removed by pipetting (damp weight). This mix was incubated at 4°C for 30 minutes before addition of another 200 mg of Biobeads (for a total 400 mg of Biobeads per 0.5 mL reaction). This final mixture was then gently tumbled at 4°C overnight (~ 12 hours). Supernatant was cleared of beads by letting large beads settle and carefully removing liquid with a pipette. Sample was spun for 10 minutes at 21,000  $\times$  g before loading onto a Superdex 200 increase column in 20 mM HEPES, 150 mM KCl, pH 7.4. Peak fractions corresponding to 3a protein in MSP1E3D1 were collected, 10 kDa cutoff spin concentrated and used for grid preparation. MSP1E3D1 was prepared as described<sup>55</sup> without cleavage of the His-tag. Tetrameric 3a in nanodiscs was prepared similarly, except with a ratio of 1:2:200 (Monomer Ratio: 3a, MSP1E3D1, lipid mixture).

### Grid Preparation

Dimeric 3a in MSP1E3D1 was prepared at final concentration of 1.1 mg/mL. For the sample with emodin (MilliporeSigma, Burlington, MA, Catalog# E7881), a stock solution of 50 mM emodin in DMSO added to protein sample for final concentrations of 1.1 mg/mL 3a and 100  $\mu$ M emodin and 1% DMSO. Concentrated sample was cleared by a 10 minute 21,000  $\times$  g spin at 4°C prior to grid making. For freezing grids, a 3  $\mu$ l drop of protein was applied to freshly glow discharged Holey Carbon, 300 mesh R 1.2/1.3 gold grids (Quantifoil, Großlobichau, Germany). A FEI Vitrobot Mark IV (ThermoFisher Scientific) was used with 4°C, 100% humidity, 1 blot force, a wait time of ~5 seconds, and a 3 second blot time, before plunge freezing in liquid ethane. Grids were then clipped and used for data collection. Tetrameric 3a in MSP1E3D1 was frozen at 0.7 mg/mL with the same grid preparation. Unimaged grids from the same session were then shipped to the Netherlands for data collection on the 300 kV microscope with Falcon 4/CFEG/Selectris energy filter.

### Cryo-EM data acquisition

For data collected on the Talos Arctica, grids were clipped and transferred to the microscope operated at 200 kV. Fifty frame movies were recorded on a Gatan K3 Summit direct electron detector in super-resolution counting mode with pixel size of 0.5685 Å. For the apo 3a dataset, the electron dose was 9.528 e<sup>-</sup> Å<sup>2</sup> s<sup>-1</sup> and 10.135 e<sup>-</sup> Å<sup>2</sup> s<sup>-1</sup> and total dose was 50.02 e<sup>-</sup> Å<sup>2</sup> and 53.72 e<sup>-</sup> Å<sup>2</sup> in the first set (1–2007) and second set (2008–6309) of movies

respectively. The two different doses are the result of needing to restart the electron gun during collection. For the 3a with added emodin dataset, the electron dose was  $8.991 \text{ e}^- \text{ \AA}^2 \text{ s}^{-1}$  and total dose was  $47.21 \text{ e}^- \text{ \AA}^2$ . For the 3a tetramer, the electron dose was  $8.841 \text{ e}^- \text{ \AA}^2 \text{ s}^{-1}$  and total dose was  $49.95 \text{ e}^- \text{ \AA}^2$ . Nine movies were collected around a central hole position with image shift and defocus was varied from  $-0.6$  to  $-2.0 \text{ \mu m}$  through SerialEM<sup>56</sup>.

For data collected for the high resolution 3a dimer structure, clipped grids from the same batch used on Talos Artica were sent to Thermo Fisher Scientific RnD division in Eindhoven, The Netherlands. Grids were loaded onto the Krios G4 microscope equipped Cold Field Emission gun (CFEG) operated at 300 kV. Data were collected on a Falcon 4 detector that was mounted behind a Selectris X energy filter. The slit width of the energy filter was set to 10eV. 5599 movie stacks containing 1429 raw frames were collected with EER (electron event representation) mode<sup>57</sup> of Falcon 4 detector at a magnification of 165 kX corresponding to a pixel size of  $0.727 \text{ \AA}$ . Each movie stack was recorded with an exposure time of 6s with a total dose of 50e/A2 on sample and a defocus range between 0.5 to 1.2  $\mu\text{m}$ .

Also see Table 1 for detailed data collection statistics.

### Cryo-EM data processing

For the apo 3a dimer, motion-correction and dose-weighting were performed on all 6,309 movies using RELION 3.1's implementation of MotionCor2, and 2x "binned" to  $1.137 \text{ \AA}$  per pixel<sup>58-60</sup>. CTFFIND-4.1 was used to estimate the contrast transfer function (CTF) parameters<sup>61</sup>. Micrographs were then manually sorted to eliminate subjectively bad micrographs, such as empty or contaminated holes, resulting in 3,611 good micrographs. Additionally, micrographs with a CTF maximum resolution lower than  $4 \text{ \AA}$  were discarded, resulting in 2,595 remaining micrographs. Template-free auto-picking of particles was performed with RELION3.1's Laplacian-of-Gaussian (LoG) filter yielding an initial set of particles. This initial set of particles were iteratively classified to generate templates, which were subsequently used to template-based auto-pick 1,750,730 particles.

Template picked particles were iteratively 2D-classified in RELION3.1 and then in cryoSPARC v2<sup>62</sup>, resulting in 820,543 particles. These particles were subsequently 3D-classified in cryoSPARC v2 with iterative ab-initio and heterogeneous refinement jobs. The resulting maps were visually evaluated with regard to the transmembrane domain density. A set of 86,479 particles were identified, polished in RELION3.1 and refined in cryoSPARC v2 with subsequent homogeneous and non-uniform refinement<sup>63</sup> jobs (maps were low-pass filtered to an initial resolution where TM density was still visible ( $6-9 \text{ \AA}$ ), and the dynamic mask was tightened with the near ( $2-5 \text{ \AA}$ ) and far ( $3-9 \text{ \AA}$ ) parameters), yielding a map with overall resolution of  $3.6 \text{ \AA}$ . UCSF pyem tools were used to convert data from cryoSPARC to RELION format<sup>64</sup>.

From this set of 86,479 particles, 2D-classification was performed in RELION3.1 to identify a set of particles with subjectively equal view distribution. From the resulting set, 1,000 particles were randomly sampled and their coordinates used for training in the Topaz particle-picking pipeline<sup>65</sup>. Training, picking, and extraction were performed

independently on each subset of the micrographs. 4,134,279 total particles were extracted in RELION3.1 with a box size of 256 pixels and “binned” 4x to 4.548 Å/pixel. These particles were then iteratively 2D-classified in RELION3.1 resulting in 2,674,606 particles which were extracted at 2.274 Å/pixel. 2D-classification was continued in both RELION3.1 and cryoSPARC v2 resulting in 1,429,763 particles. Further classification was performed in cryoSPARC v2 with subsequent ab-initio (4 classes, max resolution 8 Å) and heterogeneous refinement (8 Å initial resolution) jobs. The two best classes were selected and the particles pooled resulting in 743,800 particles which were extracted in RELION3.1 at 1.137 Å/pixel.

Iterative 3D-classification was performed with subsequent ab-initio and heterogeneous refinement jobs as described above. Following each round, 2D classification jobs were used to “rescue” good particles from the worst classes before the next round. After 3 rounds, a final 2D-classification job was used to identify 112,502 particles, which were subsequently pooled with the previous 86,479 RELION3.1 template-picked particles, resulting in 185,871 particles after duplicates (within 100 Å) were removed with RELION3.1.

These particles were then refined with subsequent homogeneous and non-uniform refinement jobs resulting in a map with overall resolution of 3.4 Å. This map was post-processed in RELION3.1 using a mask with a soft edge (5 pixel extension, 7 pixel soft-edge), the output of which was used for Bayesian particle polishing in RELION3.1 (training and polishing were each performed independently on each subset of the micrographs). The resulting “shiny” particles were then refined in cryoSPARC v2 with subsequent homogenous refinement (1 extra pass, 7 Å initial resolution) and non-uniform refinement (C2, 1 extra pass, 9 Å initial resolution) to yield a map with 2.9 Å overall resolution.

For 3a dimer with added 100 µM emodin, initial processing was similar to the dimer without added drug (see Supplemental Fig. 3). As with the apo 3a dimer, the critical steps included Topaz particle picking, particle clean-up with cryoSPARC v2 ab-initio and heterogeneous refinement, non-uniform refinement with tightened masking, and RELION3.1 Bayesian particle polishing. However, in contrast to the apo dataset, we observed a set of particles that were included in < 4 Å reconstructions that had discontinuous transmembrane domain density. Removal of these particles with RELION3.1 3D classification without angular sampling led to the best map from the emodin-added dataset. We did not see any evidence of bound emodin, but the 1% DMSO added with drug addition may have contributed to subtle map differences (Supplemental Fig. 3, Extended Data Fig. 4).

For the 3a tetramer, the initial 7,092 micrographs were first cleaned using manual inspection and removal of images with < 4 Å CtfMaxResolution to obtain a set of 4,324 micrographs. Reference particles for Topaz particle picking were generated by first template picking in RELION3.1, followed by 2D classification in both RELION3.1 and cryoSPARC v2, and subsequent ab-initio in cryoSPARC v2. Particles from various views were then selected from iterative RELION3.1 2D classification to create a set of 6,843 particles. Using these coordinates for training, Topaz particle picking was then performed to generate a set of 1,282,913 initial particles. These particles were then cleaned using 2D classification in RELION3.1 and cryoSPARC v2, followed by rounds of cryoSPARC v2 ab-initio and RELION3.1 3D classification. A major hurdle for tetramer processing was obtaining a



reconstruction where most particles were properly oriented in the same direction (i.e. ICD domains on the same side of the nanodisc as seen in the 2D classes, see Fig. 2f). Substantial cleanup by 3D-classification was needed to generate a correctly aligned reference map, but this map could then be used as a reference for refinements and classification for larger particle sets. Reconstructions with C1 or C2 symmetry looked similar (see Extended Data Fig. 2e), although no tetramer reconstruction went to high enough resolution to determine symmetry with certainty. Therefore, it is possible that either the tetramer is pseudosymmetric or that different particles have heterogeneous orientations between dimer pairs. For the tetramer, the highest resolution reconstruction came from cryoSPARC v2 non-uniform refinement with a tightened mask, which was subsequently used for dimer-docking and figure preparation.

For the apo 3a dimer imaged on a Krios with CFEG, Selectris X, and Falcon 4, the EER movie motion correction and subsequent polishing was performed in RELION3.1 using the devel-eer branch of Relion. Dose fractions consisting of 30 frames corresponding to 1.035e/A2 per fraction were created. The initial 5599 micrographs were pruned by selecting 4495 micrographs with  $< 3.5 \text{ \AA}$  CtfMaxResolution that also passed manual inspection. Similarly to the Arctica datasets, an initial set of particles was generated with template based picking and subsequent 2D classification, Ab initio, and Heterogeneous refinement for clean-up was performed in cryoSPARC v2 (See Supplemental Fig. 4). This particle set (44,944) was then used as training for the first round of Topaz particle picking. For initial particle clean-up, the most important step was heterogeneous refinement in cryoSPARC v2, yielding a particle set (215,227) that gave a C2 non-uniform refinement at 2.69  $\text{\AA}$ . For final particle clean-up, using RELION3.1, polished particles were subjected to 3D classification with no angular sampling and high tau (40) during which we monitored the rounds of classification by looking for convergence in resolution and inspecting maps to check for quality of protein features or noise. This type of job reliably allowed us to select the best particles (61,531) for high-resolution reconstruction at 2.26  $\text{\AA}$ .

At this point, a second Topaz training and picking round was conducted using this set of particles. After merging the best particles from both rounds of Topaz picking, removing potential duplicate particles within a distance of 100  $\text{\AA}$ , and subsequent processing, we obtained a set of particles (91,218) that achieved a non-uniform reconstruction at 2.17  $\text{\AA}$ . Finally, rounds of CtfRefine in cryoSPARC v2 and a final non-uniform refinement (with higher-order CTF terms enabled) achieved a map with an estimated resolution of 2.1  $\text{\AA}$ . Depending on inputs into sharpening and local resolution jobs (Extended Data Fig. 5a), the map has regions that give resolution estimates significantly below 2  $\text{\AA}$ , consistent with our observations of holes in aromatic side chain density.

We note that the merging of two Topaz picked particle sets likely allowed us to break a particle-limited barrier to achieve the final reconstruction based on ResLog<sup>66</sup> analysis performed in cryoSPARC (See Extended Data Fig. 5c). Finally, we sampled various box sizes during processing (as large as 416 pixels and as small as 256 pixels)<sup>67</sup>. The best reconstructions were consistently achieved with our final box size of 300 pixels (218.1  $\text{\AA}$ ).

## Modeling, Refinement, and Analysis

Apo dimeric 3a cryo-EM maps were sharpened using cryoSPARC and were of sufficient quality for de novo model building in Coot<sup>68</sup>. Real space refinement of the models was carried out using Phenix.real\_space\_refine<sup>69</sup>. Molprobity<sup>70</sup> was used to evaluate the stereochemistry and geometry of the structure for subsequent rounds of manual adjustment in Coot and refinement in Phenix. For final sharpening and visualization of the high-resolution map we used Phenix Resolve Density Modification<sup>71</sup>. Docking of the apo dimeric 3a into the tetrameric 3a cryo-EM map was performed in Phenix using a map in which large empty regions of the nanodisc were erased in Chimera<sup>72</sup>. Similar results were found using maps with only the CDs present. Cavity measurements were made with HOLE<sup>73</sup> implemented in Coot. Comparisons to the structure database was performed with DALI<sup>26</sup>. Structure prediction was performed with Phyre2<sup>74</sup>. Figures were prepared using PyMOL, Chimera, ChimeraX<sup>75</sup>, Fiji, Prism 8, GNU Image Manipulation Program, and Adobe Photoshop and Illustrator software.

## Fluorescence Size Exclusion Chromatography (FSEC)

Sf9 cells (~4 million) from the third day of infection were pelleted, frozen, and then thawed into extraction buffer (20mM Tris pH 8, 150 mM KCl, all protease inhibitors used for protein purification, 1 mM EDTA, 1% DDM). Extraction was performed at 4°C for 1 hour and lysate was then pelleted at 21,000 × g at 4°C for 1 hour to clear supernatant. Supernatant was then run on a Superose 6 Increase column with fluorescence detection for GFP into 20 mM HEPES pH 7.4, 150 mM KCl, .025% DDM.

## Transfection for Confocal Imaging


The constructs for full length 3a and 3a<sup>N</sup> were cloned into a vector with a CMV-promoter and C-terminal EGFP. Constructs (2 µg) were transfected into HEK293 cells on glass coverslips using Fugene HD (Promega, Madison, WI) per manufacturer's instructions. Two days after transfection cells were washed with DPBS and then fixed in 4% Formaldehyde in DPBS for 10 minutes. Cells were then washed with DPBS before mounting the coverslip with Prolong Glass Antifade with NucBlue (ThermoFisher Scientific) per manufacturer's instructions. Fluorescent images were collected using a Zeiss LSM 880 NLO AxioExaminer confocal microscope at either 20X (NA 1.0) or 63X oil immersion objective (NA 1.4). The samples were excited with 488nm argon laser and image analysis was performed using ImageJ (1.53a).

## Data and reagent availability

All data associated with this study are publicly available. For cryo-EM of dimeric apo 3a, the final model is in the PDB under 6XDC, the final map is in the EMDB under EMD-22136, and the original micrograph movies and final particle stack is in EMPIAR under EMPIAR-10439. For tetrameric apo 3a, the final map is in the EMDB under EMD-22138 and the original micrograph movies and final particle stack is in EMPIAR under EMPIAR-10441. For dimeric 3a in the presence of emodin, the final map is in the EMDB under EMD-22139 and the original micrograph movies and final particle stack is in EMPIAR under EMPIAR-10440. For the high resolution dimeric apo 3a, the final model is

in the PDB under 7KJR, the final map is in the EMDB under EMD-22898, and the original micrograph movies and final particle stack is in EMPIAR under EMPIAR-10612. For mass spectrometry searches, the *Spodoptera frugiperda* proteome was downloaded from Uniprot (<https://www.uniprot.org/uniprot/?query=taxonomy:7108>).

## Extended Data



### Extended Data Figure 1. Purification and reconstitution of 3a.

(a) Size exclusion chromatogram of 3a expressed in insect cells and extracted and purified in DDM (left). Pooled fractions corresponding to dimeric 3a are highlighted in blue.

Coomassie-stained SDS-PAGE of pooled dimeric 3a-containing fractions (center) and of


3a following reconstitution into PC lipids (right). This is a representative preparation used for 3a proteoliposome experiments. WT 3a was purified into DDM six times with similar biochemical behavior. Proteoliposomes from three Soy PC preparations were used for activity assays. (b) Size exclusion chromatogram of dimeric 3a reconstituted into MSP1E3D1 lipid nanodiscs (left). Pooled fractions are highlighted blue. 3a was incorporated into nanodiscs three separate times with similar biochemical behavior, and this representative preparation was used for dimeric 3a cryo-EM data collection (c,d) Same as (a,b), but for tetrameric 3a. The tetrameric peak has been observed in all WT 3a preparations. This representative preparation was used for cryo-EM of tetrameric 3a. (e) GFP fluorescence chromatogram of 3a expressed in SF9 cells and extracted in DDM detergent. Samples were run on a Superose 6 column.

Author Manuscript


Author Manuscript

Author Manuscript


Author Manuscript



**Extended Data Figure 2. Example micrographs and 2D class averages of 3a structures.** (a) Representative micrograph and (b) 2D class averages of dimeric apo 3a in MSP1E3D1 lipid nanodiscs. (c) Representative micrograph and (d) 2D class averages of tetrameric apo 3a in MSP1E3D1 lipid nanodiscs. (e) Map overview pipeline for final steps of tetramer processing (Also see Methods) (f) Representative micrograph and (g) 2D class averages of dimeric 3a in MSP1E3D1 lipid nanodiscs with emodin added. (h) Representative micrograph and (i) 2D class averages of the Krios/CFEG/Selectris collected dimeric apo 3a in MSP1E3D1 lipid nanodiscs (from cryoSPARC). Micrograph scale bars, 100 Å.




**Extended Data Figure 3. Cryo-EM validation for dimeric apo 3a in MSP1E3D1 lipid nanodiscs.** (a) Local resolution estimated in Relion colored as indicated on the final map. (b) Angular distribution of particles used in final refinement with final map for reference. (c) Fourier Shell Correlation (FSC) relationships (unmasked) between (black) the two unfiltered half-maps from refinement and used for calculating overall resolution at 0.143, (red) the final map and model, (gray) half-map one and model, and (blue) half-map and model.



**Extended Data Figure 4. Cryo-EM validation for dimeric 3a in MSP1E3D1 lipid nanodiscs with emodin added.**

(a) Local resolution estimated in Relion colored as indicated on the final map. (b) Angular distribution of particles used in final refinement with final map for reference. (c) Fourier Shell Correlation (FSC) relationships (masked) between (black) the two unfiltered half-maps from refinement and used for calculating overall resolution at 0.143, (red) the final map and model, (gray) half-map one and model, and (blue) half-map and model.




**Extended Data Figure 5. Cryo-EM validation for 2.1 Å dimeric apo 3a in MSP1E3D1 lipid nanodiscs.**

(a) Local resolution estimated in cryoSPARC at the indicated FSC thresholds colored as indicated on the density modified map. (b) Angular distribution of particles used in final refinement with map for reference. (c) ResLog analysis conducted in cryoSPARC at the indicated FSC thresholds. (d) Fourier Shell Correlation as calculated in cryoSPARC before (top) and after (bottom) mask auto-tightening in the final round of refinement. (e) Fourier Shell Correlation (FSC) relationships (masked) calculated in Phenix between (black) the two unfiltered half-maps from refinement and used for calculating overall resolution at 0.143,




(red) the final map and model, (gray) half-map one and model, and (blue) half-map and model. (f) Comparison of the original (2.9 Å) 3a map left to the high-resolution (2.1 Å) map before (middle) and after (right) Phenix density modification.



**Extended Data Figure 6. The dimer-dimer interface and a cysteine rich pocket in 3a.**


(a) A slice through the tetramer map with docked dimer models to illustrate the rigid body fit of model to map. Left: Same threshold as in Figure 2 (0.25). Right: At a lower threshold (0.21). (b) Dimer model (left) with boxed region zoom-in (middle) and an alternate view

(right) to show the cysteine-rich region of 3a. Distances (dotted lines) between the reduced cysteines are displayed. (c) Left: Dimers docked into the tetramer map with the solvent excluded surface of 3a colored from hydrophilic (dark cyan) to hydrophobic (dark orange). Right: “Open book” view of each dimer from the perspective of the other dimer in the tetrameric assembly. The hydrophilic groove between TM2 and TM3 is outlined.



Extended Data Figure 7. Localization of 3a-EGFP and 3a N-EGFP expressed in HEK293 cells.


(a) 3a-GFP fluorescence localization in HEK293 cells transfected with 3a-EGFP or 3a N-EGFP. Single plane and brightest-point projection are displayed for each. Scale bar, 10  $\mu\text{m}$ . (b) Side view and view from the extracellular/luminal space for dimeric 3a cryo-EM density (gray) from the original (left) and high-resolution (right) maps with unmodeled extended density above the mouth of the pore that may correspond to the N-terminal regions colored in purple. A 3a dimer model is drawn orange (TMD) and pink (CD) inside the density. The position of the final modeled N-terminal residue (S40) is indicated. (c) 3a-EGFP or 3a N-EGFP field of view with multiple cells imaged using a 20X objective. Scale bar, 20  $\mu\text{m}$ . (d) Additional images of cells imaged with the 63X objective with both single plane and brightest-point projections displayed. Scale bar, 10  $\mu\text{m}$ .



### Extended Data Figure 8. Patch recordings from 3a-proteoliposomes.

(a-c,g) Representative current recordings from 3a-proteoliposome. Currents were recorded with the following protocol:  $V_{\text{hold}} = 0$  mV,  $V_{\text{test}} = -100$  to  $100$  mV,  $V = 20$  mV,  $t_{\text{test}} = 1$  sec. Voltages indicated were corrected after recording for liquid junction potential. (a)  $150$  mM  $K^+$  (black) or  $150$  mM  $Na^+$  (pink) bath solution. (b)  $150$  mM  $K^+$  (black) or  $75$  mM  $Ca^{2+}$  (orange) bath solution. (c)  $K^+$  (black) or  $150$  mM  $NMDG^+$  (blue) bath solution. (d)  $Ba^{2+}$  does not block 3a currents. Current-voltage relationship plotted from a recording in  $150$  mM  $Na^+$  (pink) or  $150$  mM  $Na^+$  with  $50$  mM  $Ba^{2+}$  (green) bath solution. (e) Emodin does not


block 3a currents. Current-voltage relationship plotted from a recording in 150 mM Na<sup>+</sup> (pink) or 150 mM Na<sup>+</sup> with 100 μM emodin (green) bath solution. (f) pH sensitivity of 3a. Current-voltage relationship plotted from a recording in 150 mM K<sup>+</sup> pH 7.2 (black) and 150 mM K<sup>+</sup> pH 9.2 (green) bath solution. (inset) Fold activation at +100 mV at pH 9.2 (mean ± s.e.m., n=3) or pH 5.2 compared to pH 7.2 (mean ± s.e.m., n=3). (g) Representative current recordings from mock reconstituted (empty) liposome patch. (h) Gap-free current recording in symmetric 150 mM KCl held at -80 mV during bath solution exchange and washout of varying Gd<sup>3+</sup> concentrations represented by vertical green bars. Source data for parts d, e, and f are available online.



**Extended Data Figure 9. Mass spectrometry analysis of 3a and control samples.**

(a) SDS-PAGE gels with 3a and mock liposome samples prior to (left) and post (right) gel slice extraction for mass spectrometry. Approximate outline of the extracted region is shown with a dotted line. The control and 3a samples were from a liposome preparation used for both electrophysiological and fluorescence assays. (b) Same as (a), but for 3a in DDM sample (prior to liposome incorporation). This sample was from a DDM prep used for both cryo-EM and proteoliposome preparations. (c) Summary table of mass spectrometry analysis for the three analyzed samples. The only other significant hits were to human

keratin proteins from the common contaminant library. No additional hits were detected from the *G. max* (soy) search.



**Extended Data Figure 10. Purification and liposome reconstitution of 3a mutants and truncation.** Top: GFP fluorescence chromatogram (FSEC) of 3a, as well as indicated mutants and truncations, expressed in SF9 cells and extracted in DDM detergent. Samples were run on a Superose 6 column. For all other panels: Size exclusion chromatogram from a s200 column of indicated 3a constructs expressed in insect cells and extracted and purified in DDM (left), coomassie-stained SDS-PAGE of pooled dimeric 3a construct -containing fractions (center), and of 3a following reconstitution into PC lipids (right). These gels and chromatograms are from the preparations used for electrophysiological assays.

## Supplementary Material

Refer to Web version on PubMed Central for supplementary material.

## Acknowledgements

We thank Dr. Hillel Adesnik for providing emodin and for discussions. We thank Paul Tobias for computational resources at the Cal-Cryo EM facility, and Dr. James Hurley and Dr. Eva Nogales for supporting the microscopy

work. We thank Thermo Fisher Scientific for microscope access. We thank Dr. Lori Kohlstaedt for assistance with mass spectrometry. We thank Robert Rietmeijer for his gift of TRAAK proteoliposomes. We thank members of the Brohawn lab and Alex Noble for thoughtful feedback on our preprint. Finally, we would like to thank the many people at UC Berkeley and surrounding companies working during the pandemic that helped make this project possible. This work used the Vincent J Proteomics/Mass Spectrometry Laboratory at UC Berkeley, supported in part by NIH S10 Instrumentation Grant S10RR025622. SGB is a New York Stem Cell Foundation-Robertson Neuroscience Investigator. This work was funded by the New York Stem Cell Foundation, NIGMS grant GM123496, a McKnight Foundation Scholar Award, a Rose Hill Innovator Award, a Sloan Research Fellowship (to SGB), NIGMS grant GM128263 (to DMK), NSF Graduate Research Fellowship DGE1752814 (to SSM), a Howard Hughes Medical Institute Faculty Scholar Award (to DMB), and a Fast Grants Award from Emergent Ventures at the Mercatus Center, George Mason University (to DMB, SGB, and Hillel Adesnik).

## Main Text References


1. Wrapp D et al. Cryo-EM structure of the 2019-nCoV spike in the prefusion conformation. *Science* 367, 1260–1263 (2020). [PubMed: 32075877]
2. Walls AC et al. Structure, Function, and Antigenicity of the SARS-CoV-2 Spike Glycoprotein. *Cell* 183, 1735 (2020). [PubMed: 33306958]
3. Shang J et al. Structural basis of receptor recognition by SARS-CoV-2. *Nature* 581, 221–224 (2020). [PubMed: 32225175]
4. Zhang L et al. Crystal structure of SARS-CoV-2 main protease provides a basis for design of improved  $\alpha$ -ketoamide inhibitors. *Science* 368, 409–412 (2020). [PubMed: 32198291]
5. Yin W et al. Structural basis for inhibition of the RNA-dependent RNA polymerase from SARS-CoV-2 by remdesivir. *Science* 368, 1499–1504 (2020). [PubMed: 32358203]
6. Zhang Y & Kutateladze TG Molecular structure analyses suggest strategies to therapeutically target SARS-CoV-2. *Nat Commun* 11, 2920–4 (2020). [PubMed: 32523109]
7. Gordon DE et al. A SARS-CoV-2 protein interaction map reveals targets for drug repurposing. *Nature* 583, 459–468 (2020). [PubMed: 32353859]
8. Zhong X et al. Amino terminus of the SARS coronavirus protein 3a elicits strong, potentially protective humoral responses in infected patients. *Journal of General Virology* 87, 369–373 (2006).
9. Lu B et al. Humoral and cellular immune responses induced by 3a DNA vaccines against severe acute respiratory syndrome (SARS) or SARS-like coronavirus in mice. *Clin Vaccine Immunol* 16, 73–77 (2009). [PubMed: 18987164]
10. Andersen KG, Rambaut A, Lipkin WI, Holmes EC & Garry RF The proximal origin of SARS-CoV-2. *Nat Med* 26, 450–452 (2020). [PubMed: 32284615]
11. Channappanavar R, Fett C, Zhao J, Meyerholz DK & Perlman S Virus-specific memory CD8 T cells provide substantial protection from lethal severe acute respiratory syndrome coronavirus infection. *J Virol* 88, 11034–11044 (2014). [PubMed: 25056892]
12. Wang H et al. SARS-CoV-2 Proteome Microarray for Mapping COVID-19 Antibody Interactions at Amino Acid Resolution. *ACS Cent Sci* 6, 2238–2249 (2020). [PubMed: 33372199]
13. Ward D et al. An integrated in silico immuno-genetic analytical platform provides insights into COVID-19 serological and vaccine targets. *Genome Med* 13, 4–12 (2021). [PubMed: 33413610]
14. Siu K-L et al. Severe acute respiratory syndrome coronavirus ORF3a protein activates the NLRP3 inflammasome by promoting TRAF3-dependent ubiquitination of ASC. *FASEB J* 33, 8865–8877 (2019). [PubMed: 31034780]
15. Chan C-M et al. The ion channel activity of the SARS-coronavirus 3a protein is linked to its pro-apoptotic function. *Int J Biochem Cell Biol* 41, 2232–2239 (2009). [PubMed: 19398035]
16. Yue Y et al. SARS-Coronavirus Open Reading Frame-3a drives multimodal necrotic cell death. *Cell Death Dis* 9, 904–15 (2018). [PubMed: 30185776]
17. Ren Y et al. The ORF3a protein of SARS-CoV-2 induces apoptosis in cells. *Cell Mol Immunol* 17, 881–883 (2020). [PubMed: 32555321]
18. Castaño-Rodríguez C et al. Role of Severe Acute Respiratory Syndrome Coronavirus Viroporins E, 3a, and 8a in Replication and Pathogenesis. *mBio* 9, 439 (2018).
19. Silvas J et al. Contribution of SARS-CoV-2 accessory proteins to viral pathogenicity in K18 hACE2 transgenic mice. *bioRxiv* 2021.03.09.434696 (2021).



20. Lu W et al. Severe acute respiratory syndrome-associated coronavirus 3a protein forms an ion channel and modulates virus release. *Proc Natl Acad Sci U S A* 103, 12540–12545 (2006). [PubMed: 16894145]
21. Schwarz S, Wang K, Yu W, Sun B & Schwarz W Emodin inhibits current through SARS-associated coronavirus 3a protein. *Antiviral Research* 90, 64–69 (2011). [PubMed: 21356245]
22. Delcour AH Electrophysiology of unconventional channels and pores. (2015).
23. Nieva JL, Madan V & Carrasco L Viroporins: structure and biological functions. *Nat Rev Microbiol* 10, 563–574 (2012). [PubMed: 22751485]
24. Scott C & Griffin S Viroporins: structure, function and potential as antiviral targets. *Journal of General Virology* 96, 2000–2027 (2015).
25. Nakane T et al. Single-particle cryo-EM at atomic resolution. *Nature* 587, 152–156 (2020). [PubMed: 33087931]
26. Holm L & Sander C Dali: a network tool for protein structure comparison. *Trends in Biochemical Sciences* 20, 478–480 (1995). [PubMed: 8578593]
27. Dang S et al. Cryo-EM structures of the TMEM16A calcium-activated chloride channel. *Nature* 552, 426–429 (2017). [PubMed: 29236684]
28. Paulino C, Kalienkova V, Lam AKM, Neldner Y & Dutzler R Activation mechanism of the calcium-activated chloride channel TMEM16A revealed by cryo-EM. *Nature* 552, 421–425 (2017). [PubMed: 29236691]
29. Zhang M et al. Structure of the mechanosensitive OSCA channels. *Nat Struct Mol Biol* 25, 850–858 (2018). [PubMed: 30190597]
30. Jojoa-Cruz S et al. Cryo-EM structure of the mechanically activated ion channel OSCA1.2. *eLife* 7, (2018).
31. Chung M-K, Güler AD & Caterina MJ TRPV1 shows dynamic ionic selectivity during agonist stimulation. *Nat Neurosci* 11, 555–564 (2008). [PubMed: 18391945]
32. Banke TG, Chaplan SR & Wickenden AD Dynamic changes in the TRPA1 selectivity filter lead to progressive but reversible pore dilation. *Am J Physiol Cell Physiol* 298, C1457–68 (2010). [PubMed: 20457836]
33. Xu L, Tripathy A, Pasek DA & Meissner G Ruthenium red modifies the cardiac and skeletal muscle Ca(2+) release channels (ryanodine receptors) by multiple mechanisms. *J Biol Chem* 274, 32680–32691 (1999). [PubMed: 10551824]
34. Choi W, Clemente N, Sun W, Du J & Lu W The structures and gating mechanism of human calcium homeostasis modulator 2. *Nature* 576, 163–167 (2019). [PubMed: 31776515]
35. Pope L, Lolicato M & Minor DL Polynuclear Ruthenium Amines Inhibit K2P Channels via a ‘Finger in the Dam’ Mechanism. *Cell Chem Biol* 27, 511–524.e4 (2020). [PubMed: 32059793]
36. Xie L-H, John SA & Weiss JN Spermine block of the strong inward rectifier potassium channel Kir2.1: dual roles of surface charge screening and pore block. *J Gen Physiol* 120, 53–66 (2002). [PubMed: 12084775]
37. Suma A, Granata D, Thomson AS, Carnevale V & Rothberg BS Polyamine blockade and binding energetics in the MthK potassium channel. *J Gen Physiol* 152, 6726 (2020).
38. Surprenant A, Rassendren F, Kawashima E, North RA & Buell G The cytolytic P2Z receptor for extracellular ATP identified as a P2X receptor (P2X7). *Science* 272, 735–738 (1996). [PubMed: 8614837]
39. Karasawa A, Michalski K, Mikhelzon P & Kawate T The P2X7 receptor forms a dye-permeable pore independent of its intracellular domain but dependent on membrane lipid composition. *eLife* 6, 3393 (2017).
40. Hadfield J et al. Nextstrain: real-time tracking of pathogen evolution. *Bioinformatics* 34, 4121–4123 (2018). [PubMed: 29790939]
41. Müller MA et al. Human Coronavirus NL63 Open Reading Frame 3 encodes a virion-incorporated N-glycosylated membrane protein. *Virol J* 7, 1–12 (2010). [PubMed: 20044930]
42. Wang K et al. PEDV ORF3 encodes an ion channel protein and regulates virus production. *FEBS Letters* 586, 384–391 (2012). [PubMed: 22245155]


43. Zhang R et al. The ORF4a protein of human coronavirus 229E functions as a viroporin that regulates viral production. *Biochimica et Biophysica Acta (BBA) - Biomembranes* 1838, 1088–1095 (2014). [PubMed: 23906728]
44. Miao G et al. ORF3a of the COVID-19 virus SARS-CoV-2 blocks HOPS complex-mediated assembly of the SNARE complex required for autolysosome formation. *Dev Cell* (2020). doi:10.1016/j.devcel.2020.12.010
45. Ghosh S et al.  $\beta$ -Coronaviruses Use Lysosomes for Egress Instead of the Biosynthetic Secretory Pathway. *Cell* 183, 1520–1535.e14 (2020). [PubMed: 33157038]
46. Zhao J, Zhao J & Perlman S T cell responses are required for protection from clinical disease and for virus clearance in severe acute respiratory syndrome coronavirus-infected mice. *J Virol* 84, 9318–9325 (2010). [PubMed: 20610717]
47. Dietl P, Haller T & Frick M Spatio-temporal aspects, pathways and actions of Ca(2+) in surfactant secreting pulmonary alveolar type II pneumocytes. *Cell Calcium* 52, 296–302 (2012). [PubMed: 22591642]
48. del Mármol J, Rietmeijer RA & Brohawn SG in *Potassium Channels: Methods and Protocols* (eds. Shyng S-L, Valiyaveetil FI & Whorton M) 129–150 (Springer New York, 2018).
49. Xu T et al. ProLuCID: An improved SEQUEST-like algorithm with enhanced sensitivity and specificity. *J Proteomics* 129, 16–24 (2015). [PubMed: 26171723]
50. Tabb DL, McDonald WH & Yates JR DTASelect and Contrast: tools for assembling and comparing protein identifications from shotgun proteomics. *J Proteome Res* 1, 21–26 (2002). [PubMed: 12643522]
51. Park SK, Venable JD, Xu T & Yates JR A quantitative analysis software tool for mass spectrometry-based proteomics. *Nat Methods* 5, 319–322 (2008). [PubMed: 18345006]
52. McDonald WH et al. MS1, MS2, and SQT-three unified, compact, and easily parsed file formats for the storage of shotgun proteomic spectra and identifications. *Rapid Commun Mass Spectrom* 18, 2162–2168 (2004). [PubMed: 15317041]
53. Peng J, Elias JE, Thoreen CC, Licklider LJ & Gygi SP Evaluation of multidimensional chromatography coupled with tandem mass spectrometry (LC/LC-MS/MS) for large-scale protein analysis: the yeast proteome. *J Proteome Res* 2, 43–50 (2003). [PubMed: 12643542]
54. Schöneberg J et al. ATP-dependent force generation and membrane scission by ESCRT-III and Vps4. *Science* 362, 1423–1428 (2018). [PubMed: 30573630]
55. Ritchie TK et al. Chapter 11 - Reconstitution of membrane proteins in phospholipid bilayer nanodiscs. *Methods Enzymol* 464, 211–231 (2009). [PubMed: 19903557]
56. Mastrorade DN Automated electron microscope tomography using robust prediction of specimen movements. *Journal of Structural Biology* 152, 36–51 (2005). [PubMed: 16182563]
57. Guo H et al. Electron-event representation data enable efficient cryoEM file storage with full preservation of spatial and temporal resolution. *IUCrJ* 7, 860–869 (2020).
58. Zheng SQ et al. MotionCor2: anisotropic correction of beam-induced motion for improved cryo-electron microscopy. *Nat Methods* 14, 331–332 (2017). [PubMed: 28250466]
59. Zivanov J, Nakane T & Scheres SHW A Bayesian approach to beam-induced motion correction in cryo-EM single-particle analysis. *IUCrJ* 6, 5–17 (2019).
60. Zivanov J et al. New tools for automated high-resolution cryo-EM structure determination in RELION-3. *eLife* 7, 163 (2018).
61. Rohou A & Grigorieff N CTFFIND4: Fast and accurate defocus estimation from electron micrographs. *Journal of Structural Biology* 192, 216–221 (2015). [PubMed: 26278980]
62. Punjani A, Rubinstein JL, Fleet DJ & Brubaker MA cryoSPARC: algorithms for rapid unsupervised cryo-EM structure determination. *Nat Methods* 14, 290–296 (2017). [PubMed: 28165473]
63. Punjani A, Zhang H & Fleet DJ Non-uniform refinement: adaptive regularization improves single-particle cryo-EM reconstruction. *Nat Methods* 17, 1214–1221 (2020). [PubMed: 33257830]
64. Asarnow D, Palovcak E & Cheng Y asarnow/pyem: UCSF pyem v0.5. (2019). doi:10.5281/zenodo.3576630

65. Bepler T et al. Positive-unlabeled convolutional neural networks for particle picking in cryo-electron micrographs. *Nat Methods* 16, 1153–1160 (2019). [PubMed: 31591578]
66. Stagg SM, Noble AJ, Spilman M & Chapman MS ResLog plots as an empirical metric of the quality of cryo-EM reconstructions. *Journal of Structural Biology* 185, 418–426 (2014). [PubMed: 24384117]
67. Herzik MA, Wu M & Lander GC High-resolution structure determination of sub-100 kDa complexes using conventional cryo-EM. *Nat Commun* 10, 1032–9 (2019). [PubMed: 30833564]
68. Emsley P, Lohkamp B, Scott WG, Cowtan KIUCr. Features and development of Coot. *Acta Crystallogr Sect D Biol Crystallogr* 66, 486–501 (2010). [PubMed: 20383002]
69. Liebschner D et al. Macromolecular structure determination using X-rays, neutrons and electrons: recent developments in Phenix. *Acta Crystallogr D Struct Biol* 75, 861–877 (2019). [PubMed: 31588918]
70. Williams CJ et al. MolProbity: More and better reference data for improved all-atom structure validation. *Protein Sci* 27, 293–315 (2018). [PubMed: 29067766]
71. Terwilliger TC, Ludtke SJ, Read RJ, Adams PD & Afonine PV Improvement of cryo-EM maps by density modification. *Nat Methods* 17, 923–927 (2020). [PubMed: 32807957]
72. Pettersen EF et al. UCSF Chimera--a visualization system for exploratory research and analysis. *J Comput Chem* 25, 1605–1612 (2004). [PubMed: 15264254]
73. Smart OS, Neduvilil JG, Wang X, Wallace BA & Sansom MS HOLE: a program for the analysis of the pore dimensions of ion channel structural models. *J Mol Graph* 14, 354–60–376 (1996). [PubMed: 9195488]
74. Kelley LA, Mezulis S, Yates CM, Wass MN & Sternberg MJE The Phyre2 web portal for protein modeling, prediction and analysis. *Nat Protoc* 10, 845–858 (2015). [PubMed: 25950237]
75. Goddard TD et al. UCSF ChimeraX: Meeting modern challenges in visualization and analysis. *Protein Sci* 27, 14–25 (2018). [PubMed: 28710774]




### Figure 1. Structure of dimeric 3a in lipid nanodiscs

(a) Cryo-EM map of the 3a dimer in MSP1E3D1 nanodiscs at 2.1 Å nominal resolution viewed from the membrane plane. One subunit is colored gray and the second subunit is colored with transmembrane region orange and cytosolic domain (CD) pink. Density from the nanodisc MSP1E3D1 is colored tan and the DOPE lipid is coral. (b,c) Model of dimeric 3a viewed (b) from the membrane (as in (a)) and (c) from the extracellular or luminal side. (d) Zoomed in view of the interaction between subunits in the CD with residues forming the hydrophobic core indicated. (e) Schematic of a 3a monomer. Secondary structure elements are indicated and unmodeled termini and a 5 amino acid  $\beta$ 3- $\beta$ 4 loop are shown with dashed lines. (f) Cryo-EM density and model for a selected strand from the CD at two different thresholds. (g) Zoomed-in view of density in the MSP1E3D1 interaction region. (h) Model in the same region as (g) with key residues in the area displayed as sticks.




**Figure 2. Structure of tetrameric 3a in lipid nanodiscs**

(a) Two-dimensional class average of tetrameric 3a in MSP1E3D1 lipid nanodiscs (above) and cryo-EM map at 6.5 Å nominal resolution (lower). (b) Approximate assembly of 3a tetramers. Two 3a dimer structures are rigid-body fit into the tetrameric cryo-EM map. (c) Zoomed in view of the interface between 3a dimers observed after rigid-body fitting with residues potentially mediating the interaction displayed as sticks.



**Figure 3. The 3a polar cavity and tunnels**

(a) View of a 3a dimer from the membrane plane with key regions labeled and with planes (dotted lines) and viewing direction (arrow) for (g-i) indicated. (b) The 3a upper tunnel with solvent-excluded surface shown for each subunit and water molecules shown as light blue spheres. The approximate lipid bilayer region is marked by black lines. One 3a subunit is colored orange and the other in gray. (c) (Left) Model of 3a (gray) with the HOLE path through the upper tunnel shown in transparent cyan. Lipid (coral) is displayed as sticks. (Middle) Radius of the upper tunnel as a function of distance from the cavity center calculated with HOLE. (Right) View into the upper tunnel from the membrane with key residues shown as sticks. (d) As in (b), for a view of the lower tunnel. (e) As in (c), for the lower tunnel, with the view on the right into the tunnel from the cytosol. (f) The intersubunit tunnel with bound DOPE lipid (coral) shown as space-filling spheres. (Right-top) Zoomed-in view of the lipid interaction with key residues shown as sticks. (Right-bottom) Cut-through view of the cryo-EM density of the lipid interaction region viewed from the cytosolic side. (g-i) Model and transparent surface of the viewing planes indicated in (a). Water molecules are shown as light blue spheres. One 3a subunit is colored orange and the other in gray. (j) The solvent excluded surface of 3a colored from hydrophilic (dark cyan) to most hydrophobic (dark orange). A membrane-facing hydrophilic groove is outlined. (k) Key residues in the hydrophilic groove are depicted as sticks colored in dark cyan.




**Figure 4. Function and inhibition of purified and reconstituted SARS-CoV-2 3a**

(a) Current-voltage relationship from a 3a-proteoliposome patch. Pipette solution was 150 mM  $K^+$  and external solution was 150 mM  $K^+$  (black), 150 mM  $Na^+$  (pink), 75 mM  $Ca^{2+}$  (orange), or 150 mM NMDG $^+$  (blue) (mean  $\pm$  s.e.m.,  $n = 3$  recordings from a representative patch). (b) Reversal potential. Pipette solution was 150 mM  $K^+$  and external solution was 150 mM  $K^+$  (black), 150 mM  $Na^+$  (pink), 75 mM  $Ca^{2+}$  (orange), or 150 mM NMDG $^+$  (blue) (mean  $\pm$  s.e.m.,  $n = 4, 4, 12,$  and  $4$  patches, respectively). One-way ANOVA with Dunnett correction,  $*p < 0.05$ ,  $**p < 0.01$ ,  $***p < 0.001$ ,  $****p < 0.0001$ ). (c) Permeability ratios ( $P_{X^+}/P_{K^+}$ ) calculated from (b). Pipette solution was 150 mM  $K^+$  and external solution was 150 mM  $K^+$  (black), 150 mM  $Na^+$  (pink), 75 mM  $Ca^{2+}$  (orange), or 150 mM NMDG $^+$  (blue) (mean  $\pm$  s.e.m.,  $n = 4, 4, 12,$  and  $4$  patches, respectively). One-way ANOVA with Dunnett correction,  $*p < 0.05$ ,  $**p < 0.01$ ,  $***p < 0.001$ ,  $****p < 0.0001$ ). (d) Gap-free current recording held at  $-80$  mV during bath solution exchanges indicated in the bar above the current trace. (e) Histogram of peak calcium influx ( $F_{max}/F_0$ ) measured by Fluo-5N fluorescence following the addition of 8mM  $[Ca^{2+}]_{ext}$  to 3a liposomes (blue) or empty liposomes (gray). For the inset graph, mean  $\pm$  SEM of peak calcium influx for 3a liposomes, empty liposomes, and 3a liposomes incubated in 200  $\mu$ M ruthenium red. (one-way ANOVA ( $F_{(2,4945)} = 99.01$ );  $n = 1,219, 2,178$  and  $1,551$  liposomes per group respectively with Dunnett's multiple-comparison test,  $**** p < 0.0001$ ). (f) Gap-free current recording in symmetric 150 mM KCl held at  $-80$  mV during bath solution exchanges of varying ruthenium red concentrations indicated in the bar below the current trace; boxed inset: magnified channel openings and closures selected from the region indicated. (g) Normalized activity in symmetric 150 mM KCl at different concentrations of ruthenium red with fit (black line) and 95% confidence interval (red) shown (mean  $\pm$  sem,  $n = 3$  patches,  $IC_{50} = 90 \pm 10 \mu$ M). (h) Normalized 3a activity in symmetric 150 mM KCl and (from left to right) no blocker, 1  $\mu$ M ruthenium red ( $p = 0.9127$ ), 10  $\mu$ M ruthenium red ( $p < 0.001$ ),


100  $\mu\text{M}$  ruthenium red ( $p < 0.0001$ ), 500  $\mu\text{M}$  ruthenium red ( $p < 0.0001$ ), 1 mM spermidine ( $p < 0.0001$ ), 10 mM spermidine ( $p < 0.0001$ ), 0.1 mM  $\text{Gd}^{3+}$  ( $p = 0.0441$ ), 1 mM  $\text{Gd}^{3+}$  ( $p < 0.0001$ ), 10 mM  $\text{Gd}^{3+}$  ( $p < 0.0001$ ), 1 mM  $\text{Fe}^{3+}$  ( $p < 0.0001$ ), and 1 mM  $\text{Tb}^{3+}$  ( $p < 0.0001$ ) (mean  $\pm$  sem,  $n = 3$  patches for each, one-way ANOVA with Dunnett correction, \* $p < 0.05$ , \*\* $p < 0.01$ , \*\*\* $p < 0.001$ , \*\*\*\* $p < 0.0001$ ). Source data for parts a,b,c,e,g, and h are available online.





### Figure 5. A flux assay of SARS-CoV-2 3a channel activity

(a-c) Histograms from quantified images following a 10-minute incubation in 10  $\mu M$  YO-PRO-1 for (a) empty liposomes, (b) 3a liposomes, or (c) TRAAK liposomes ( $n = 255, 3046,$  and  $1408$  for empty, 3a, and TRAAK liposomes). Dotted red line indicates the position of the mean fluorescence of empty liposomes. (Insets) Representative images with YO-PRO-1 fluorescence (green) overlaid on brightfield. Scale bar =  $20 \mu m$ . (d) Fraction of YO-PRO-1-positive liposomes (mean  $\pm$  SD,  $n = 9, 10$  and  $10$  independent replicates for empty, 3a, and TRAAK liposomes with  $500$ – $5,000$  liposomes per replicate,  $p = 0.0004$  (one-way ANOVA ( $F_{(2,26)} = 10.52$ )), Tukey's multiple-comparison test:  $p_{\text{empty vs. 3a}} = 0.0004$ ;  $p_{\text{TRAAK vs. 3a}} = 0.0113$ ;  $p_{\text{empty vs. TRAAK}} = 0.3571$ ). (e) Area under the curve (AUC) of YO-PRO-1 fluorescence histograms of the fraction of liposomes that took up YO-PRO-1 per well (mean  $\pm$  SD,  $n = 9, 10$  and  $10$  independent replicates for empty, 3a, and TRAAK liposomes with  $500$ – $5,000$  liposomes per replicate,  $p < 0.0001$  (Welch's ANOVA test ( $W_{(2,16.68)} = 13.22$ )), Dunnett's multiple-comparison test:  $p_{\text{empty vs. 3a}} = 0.0005$ ;  $p_{\text{TRAAK vs. 3a}} = 0.0041$ ;  $p_{\text{empty vs. TRAAK}} = 0.4178$ ). (f) YO-PRO-1 uptake in 3a-liposomes is inhibited by ruthenium red. Mean  $\pm$  SD, sigmoidal fit (black dotted line) and  $IC_{50}$  are shown. Source data for parts a-f are available online.



**Figure 6. Modification of 3a alters channel activity**

(a) Two views of 3a from the membrane plane with the positions of 3a mutations and truncation indicated. (b) Permeability ratios ( $P_{X^+}/P_{K^+}$ ) calculated from reversal potential shifts for 3a mutations and N truncation (mean  $\pm$  s.e.m., n=8, 3, 3, 7, 2, 4, 7, 8, 9, and 3 patches for wild-type, S58K ( $p = 0.2352$ ), C81E ( $p = 0.1741$ ), N119K ( $p = 0.9971$ ), D142K ( $p = 0.9997$ ), Q57H ( $p = 0.9005$ ), Q57K ( $p = 0.2220$ ), Q57E ( $p < 0.0001$ ), S58L, Q116L ( $p < 0.0001$ ), and N (For Ca<sup>2+</sup>  $p = 0.0251$  and for NMDG<sup>+</sup>  $p = 0.0287$ ), respectively, \* $p < 0.05$ , \*\*\*\* $p < 0.0001$ , one-way ANOVA with Dunnett correction for multiple comparisons). Source data for part b are available online.

Table 1

Cryo-EM data collection, refinement and validation statistics

	Dimeric apo 3a (EMD-22136, PDB 6XDC, EMPIAR-10439)	3a Dimer + Emodin (EMD-22139, EMPIAR-10440)	Tetrameric apo 3a (EMD-22138, EMPIAR-10441)	Dimeric apo 3a (EMD-22898, PDB 7KJR, EMPIAR-10612)
<b>Data collection and processing</b>				
Magnification	36,000 x	36,000 x	36,000 x	165,000 x
Voltage (kV)	200	200	200	300
Electron exposure ( $e^-/\text{\AA}^2$ )	50.325 or 53.72	47.21	49.95	50
Defocus range ( $\mu\text{m}$ )	-0.6 to -2.0	-0.6 to -2.0	-0.6 to -2.0	-0.5 to -1.1
Super resolution pixel size ( $\text{\AA}$ )	0.5685	0.5685	0.5685	0.3685
Binned pixel size ( $\text{\AA}$ )	1.137	1.137	1.137	0.737
Symmetry imposed	C2	C2	C2	C2
Initial particle images (no.)	4,134,279	3,873,767	1,282,913	2,314,293
Final particle images (no.)	185,871	51,908	64,410	91,218
Map resolution ( $\text{\AA}$ )	2.9	3.69	6.5	2.08
FSC threshold	0.143	0.143	0.143	0.143
<b>Refinement</b>				
Initial model used (PDB code)	<i>de novo</i>			6XDC
Model resolution ( $\text{\AA}$ )	3.2			2.0
FSC threshold	0.143			0.143
Map sharpening <i>B</i> factor ( $\text{\AA}^2$ )	-111.2			-43.5
Model composition				
Nonhydrogen atoms	3150			3840
Protein residues	386			448
Ligands				2
<i>B</i> factors ( $\text{\AA}^2$ )				
Protein	108.61			23.30
Ligand				51.72
R.m.s. deviations				
Bond lengths ( $\text{\AA}$ )	0.006			0.005
Bond angles ( $^\circ$ )	0.785			0.729
<b>Validation</b>				
MolProbity score	1.55			1.42
Clashscore	4.63			7.60
Poor rotamers (%)	1.15			0.25
Ramachandran plot				
Favored (%)	96.03			98.17
Allowed (%)	3.97			1.13
Disallowed (%)	0			0

Table 2

3a homologs across *Coronaviridae*

Proposed host origin		Subgenus / Species	Annotated ORF name	Accession	Phyre predicted amino acid range	Phyre confidence score	
Bat	Alphacoronavirus	<b>Colacovirus</b>					
		Bat coronavirus CDPHE15 (1384461)	NS3	YP_008439203.1	69 – 222	98%	
		<b>Decacovirus</b>					
		Bat coronavirus HKU10 (1244203)	NS3	AFU92105.1	69 – 221	96%	
		R. ferrumequinum HuB-2013 (2501926)	ORF3	YP_009199791.1	69 – 220	97%	
		<b>Duvinacovirus</b>					
		Human coronavirus 229E (11137)	ORF4	ARU07602.1	69 – 221	95%	
		<b>Luchacovirus</b>					
		Coronavirus AcCoV-JC34 (1964806)	ORF3	YP_009380522.1	69 – 220	96%	
		<b>Minacovirus</b>					
		Mink coronavirus 1 (766791)	NS3	YP_009019183.1	68–221	96%	
		<b>Minunacovirus</b>					
		Miniopter bat coronavirus 1 (694000)	ORF3	ACA52165.1	69 – 221	96%	
		Miniopter bat coronavirus HKU8 (694001)	ORF3	AIA62228.1	69 – 221	96%	
		<b>Myotacovirus</b>					
		Myotis ricketti alphacoronavirus Sax-2011 (2501927)	ORF3	AIA62247.1	78–211	97%	
		<b>Nyctacovirus</b>					
		Nyctalus velutinus alphacoronavirus SC-2013 (2501928)	ORF3	YP_009201731.1	69 – 220	97%	
		Pipistrellus kuhlii coronavirus 3398 (2492658)	ORF3	YP_009755891.1	69 – 220	97%	
		<b>Pedacovirus</b>					
Porcine epidemic diarrhea virus (28295)	ORF3	AWM99571.1	69 – 221	96%			
Scotophilus bat coronavirus 512 (693999)	ORF3	YP_001351685.1	69 – 220	97%			
<b>Rhinacovirus</b>							
Rhinolophus bat coronavirus HKU2 (693998)	ORF3	ATN23890.1	69 – 220	97%			
<b>Setracovirus</b>							
Human coronavirus NL63 (277944)	ORF3	AGT51388.1	69 – 221	97%			

Proposed host origin		Subgenus / Species	Annotated ORF name	Accession	Phyre predicted amino acid range	Phyre confidence score	
Author Manuscript		NL63-related bat coronavirus BtKYNL63-9b (1920748)	ORF3	YP_009824968.1	69 – 220	96%	
		<b>Tegacovirus</b>					
		Alphacoronavirus 1 (693997)	NSP3B	AEM55568.1	69 – 220	96%	
	Author Manuscript	<b>Betacoronavirus</b>	<b>Sarbecovirus</b>				
			Human SARS-CoV-1 (694009)	ORF3A	P59632	42–237	100%
			Human SARS-CoV-2 (2697049)	ORF3A	YP_009724391.1	n/a	n/a
			<b>Hibecovirus</b>				
			Bat Hp-betacoronavirus Zhejiang2013 (1541205)	ORF3	YP_009072441.1	42–236	100%
			Zaria bat coronavirus (989337)	ORF3	ADY17912.1	101–233	100%
			<b>Nobecovirus</b>				
			Eidolon bat coronavirus C704 (983924)	ORF3	ADX59467.1	123–190	96%
			Rousettus bat coronavirus GCCDC1 (1892416)	NS3	YP_009273006.1	122–209	95%
			Rousettus bat coronavirus HKU9 (694006)	NS3	QJX58367.1	122–209	95%
			<b>Merbecovirus</b>				
			Human Middle East respiratory syndrome-related (1335626)	ORF5	QJX19961.1	119–146	88%
			Hedgehog coronavirus 1 (1965093)	ORF5	QCC20718.1	126–205	86%
Pipistrellus bat coronavirus HKU5 (694008)	ORF5	AWH65914.1	126–182	92%			
Tylonycteris bat coronavirus HKU4 (694007)	ORF5	AWH65903.1	126–182	91%			
Author Manuscript	<b>Rodent</b>	<b>Embecovirus</b>					
		Betacoronavirus 1 (694003)	none	none	none	none	
		China Rattus coronavirus HKU24 (2501960)	none	none	none	none	
		Human coronavirus HKU1 (290028)	none	none	none	none	
		Murine coronavirus (694005)	none	none	none	none	
		Myodes coronavirus 2JL14	none	none	none	none	
Author Manuscript	<b>Avian / Pig</b>	<b>Deltacoronavirus</b>					
		Wigeon coronavirus HKU20 (1159908)	none	none	none	none	

Proposed host origin		Subgenus / Species	Annotated ORF name	Accession	Phyre predicted amino acid range	Phyre confidence score
		<b>Buldecovirus</b>				
		Bulbul coronavirus HKU11 (574549)	none	none	none	none
		Common moorhen coronavirus HKU21	none	none	none	none
		Coronavirus HKU15 (1965089)	none	none	none	none
		Munia coronavirus HKU13 (1297661)	none	none	none	none
		White-eye coronavirus HKU16 (1159907)	none	none	none	none
		<b>Herdecovirus</b>				
	Night heron coronavirus HKU19	none	none	none	none	
	<b>Gammacoronavirus</b>	<b>Brangacovirus</b>				
		Goose coronavirus CB17	none	none	none	none
		<b>Cegacovirus</b>				
		Beluga whale coronavirus SW1 (694015)	none	none	none	none
		<b>Igacovirus</b>				
		Avian coronavirus (694014)	none	none	none	none
Avian coronavirus 9203		none	none	none	none	
Duck coronavirus 2714 (300188)	none	none	none	none		

Author Manuscript

Author Manuscript

Author Manuscript

Author Manuscript